Seton Hall University

eRepository @ Seton Hall
Seton Hall University Dissertations and Theses
(ETDs)

Seton Hall University Dissertations and Theses

Spring 3-6-2019

Meta-analysis to Identify and Evaluate Factors
Associated with Regulatory Approval of Orphan
Drugs (OD) to Develop an Algorithm for
Predicting Regulatory Approval (Success) and to
Develop a Standardized Tool to Improve Orphan
Drug Portfolio Decision-making
Milky C. Florent
florenmi@shu.edu

Follow this and additional works at: https://scholarship.shu.edu/dissertations
Part of the Medicinal and Pharmaceutical Chemistry Commons, and the Pharmacy
Administration, Policy and Regulation Commons
Recommended Citation
Florent, Milky C., "Meta-analysis to Identify and Evaluate Factors Associated with Regulatory Approval of Orphan Drugs (OD) to
Develop an Algorithm for Predicting Regulatory Approval (Success) and to Develop a Standardized Tool to Improve Orphan Drug
Portfolio Decision-making" (2019). Seton Hall University Dissertations and Theses (ETDs). 2629.
https://scholarship.shu.edu/dissertations/2629

Meta-analysis to identify and evaluate factors associated with regulatory approval of
orphan drugs (OD) to develop an algorithm for predicting regulatory approval (success)
and to develop a standardized tool to improve orphan drug portfolio decision-making

By Milky C. Florent

Dissertation Committee:
Deborah A. DeLuca, M.S., JD (Chair)
Terrence F. Cahill, Ed.D., FACHE
Glenn Beamer, Ph.D.

Submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy in
Health Sciences
Seton Hall University
2019

© 2019 Milky C Florent
All Rights Reserved

iv
ACKNOWLEDGMENTS

I would like to thank all the people without whom this project would never have been
possible.
I would like to acknowledge my dissertation committee members: Dr. DeLuca, Dr. Cahill
and Dr. Beamer, who accepted and welcomed my study and encouraged me to pursue my research
on orphan drugs. A special thanks to Dr. Debora DeLuca (Chair) her enthusiasm, inspiration, and
great efforts to explain things clearly and simply helped to make this study fun for me. Throughout
my thesis-writing period, she provided sound advice, good teaching, good company, and lots of
good ideas.

To all my friends and work colleagues who have supported me along this journey.

To my lovely husband Walter, I thank you for always pushing me to be the best version
of myself.

To my parents, Milko and Onelia and my sister Naiky I thank you for your unconditional
love and support. You are all examples of commitment, excellence and success. I love you.

v
DEDICATION
This dissertation research is dedicated to all the people in the World who are currently
suffering any physical and mental illness.

“He who has health has hope; and he who has hope, has everything”
Thomas Carlyle.

vi
TABLE OF CONTENTS
ACKNOWLEDMENTS ………………………………………………………….……

iv

DECICATION ……………………………………………………………………..…..

v

LIST OF TABLES ………………………………………………………………..…… ix
LIST OF FIGURES …………………………………………………………………… x
ABSTRACT…………………………………………………………………………….. xi
I.

INTRODUCTION …………………………………………………….…….…

1

Problem Background …………………………………………………………....

1

Problem Statement …………………………………………………………........ 3
Purpose of the Study …………………………………………………………..... 3

II.

Research Questions …………………………………………………………….

4

Research Hypotheses ……………………………………………………………

4

Significance of the Study ………………………………………………………

5

Operational Definitions …………………………………………………………

10

LITERATURE REVIEW …………………………………………………….

15

Rare Disease Definition and Prevalence ………………………………………

15

Rare Disease Characteristics ……………………………………………………. 16
Orphan Drugs Definition and Classification ………………………….………...

16

United States Patent and Trademark Office (US PTO) ……………..…………..

17

United States Food and Drug Administration (US FDA) ………...…………….. 19
The United States Orphan Drug Act (ODA) ……………………………………

22

Orphan Drug Act Incentives ……………………………………………………. 25
Impact of Orphan Drugs on FDA Orphan Drug Designations (ODD)……….…. 30
Risks Associated with Orphan Drug Research and Development ……………… 32
Assessing Risk of Orphan Drug Regulatory Approval ……….………………… 35
Net Present Value (NPV) ……………………………….………………………. 39

vii
THEORETICAL FRAMEWORK ……………………………………… 42
1. Orphan Drug Research and Development …………………………

42

2. Intellectual Property Strategy for Orphan Drugs …………………… 48
3. The Orphan Business Model of Orphan Drugs ……………………

53

CONCEPTUAL FRAMEWORK ………………………………………. 58
III.

METHODOLOGY ……………………………………………………….……

60

Introduction ……………………………………………………………..………. 60
Research Design ……………………………………………………………...…

62

Institutional Review Board (IRB) ………………………………………………

62

Data Collection ………………………………………………………………….

65

Methodology ……………………………………………………………………. 65
1. Systematic Review ………………………………………………………….. 65
2. Meta-Analysis ………………………………………………………………. 68
2.1 Inclusion and Exclusion Criteria ……….………………………………

73

2.2 Validity and Reliability ………………................................................…

75

3. Statistical Analysis ………………………………………………………….. 76
Software ………………………………………………………………………… 77
IV.

RESULTS ……………………………………………………………...….……

81

PART I: Exploratory Research …………………………………...…………….. 81
1. Summary of Findings from Systematic Review………………………… 81
2. Summary of Findings from Meta-Analysis ……………………………

83

3. Summary of Findings from Meta-Regression ..………………………

85

Summary PART I……………………………………………………………….

89

PART II: Building an algorithm of Approved Orphan Drugs Index (AODI) …..

90

1. Construction of AODI …………………………………………………..

90

2. Validation and standardization of AODI ………………………………

91

Summary PART 2 .…………………………………………………………….

93

viii
V.

DISCUSSION …………………………………………………….……….…… 94
PART I: Exploratory Research …………………………………………………. 94
PART II: Building an Algorithm of Approved Orphan Drugs Index (AODI) ….

101

Revised Conceptual Framework ………………………………………………... 105
Revised Algorithm for Orphan Drug Regulatory Assessment ……………….....

106

Study Limitations ……………………………………………………………….. 109
VI.

CONCLUSION …………………………………………………….…………..

111

Future Research …………………………………………………………………

112

Dissertation Significance and Conclusion ………………………………………

112

REFERENCES ………………………………………………………………………...

114

APPENDIX A Letter to Institutional Review Board (IRB) ……………………......

117

APPENDIX B First Letter from Institutional Review Board (IRB)………………

118

APPENDIX C Second Letter from Institutional Review Board (IRB) ……………

119

APPENDIX D Meta-data (raw data) File …………………………………………..

120

ix
LIST OF TABLES
Table I.

Orphan Drug Legislation in US and Major Markets ……………….

25

Table II.

Orphan Drugs Approval Process in US …………………………….

50

Table III.

Intellectual Property Strategies……….……………………………..

56

Table IV.

Data Selection: Meta-Analysis Inclusion and Exclusion Criteria…..

74

Table V.

Predominant areas of Research of Orphan Drug (OD) Literature.…

81

Table VI.

Sub-categories within Research and Development (R&D) ………...

82

Table VII.

Sub-categories within Orphan Drug Policy ………..………………

82

Table VIII.

Sub-categories within Orphan Drug Business Model ………..……..

83

Table IX.

Factors associated with Probability of Regulatory Success (PRS) of
Orphan Drug (OD) ………………………………………………….

Table X.

84

Univariate Association (together) between Potential Predictive
Factors and Probability of Regulatory Success (PRS) of Orphan
Drugs (OD)………..………………….……………………………..

Table XI.

85

Univariate Association (isolation) between Potential Predictive
Factors and Probability of Regulatory Success (PRS) of Orphan
Drugs (OD) ………………………………………………………....

87

Table XII.

Summary of PART I: Exploratory Research………………..……....

89

Table XIII.

Approved Orphan Drugs Index (AODI) ……………………………

90

Table XIV.

Summary of PART II: Building an Algorithm…………….………..

93

Table XV.

Univariate Association (together) between Potential Predictive
Factors and Probability of Regulatory Success (PRS) of Orphan
Drugs (OD)………..……………..………………………………….

Table XVI.

97

Univariate Association (isolation) between Potential Predictive
Factors and Probability of Regulatory Success (PRS) of Orphan
Drugs (OD) …………………………………………………………

99

Table XVII.

Approved Orphan Drugs Index (AODI) ………………………...….

101

Table XVIII.

FDA Clinical Trails (phase II interventional studies) 1999-2017 …

102

x
LIST OF FIGURES
Figure 1.

Paradox of Rare Diseases ……………………………….……………...

15

Figure 2.

FDA Organizational Chart ……………………………….……………

21

Figure 3.

Orphan Drug Legislation Status Worldwide……………….……………

24

Figure 4.

Orphan Drug Designation Process …………………………………….

28

Figure 5.

FDA Orphan Drugs Approvals 1983-2017 ……………………………

30

Figure 6.

Standard Probability of Regulatory Success (PRS) Model ……………...

37

Figure 7.

Probability of Regulatory Success (PRS) examples …………………….

38

Figure 8.

Net Present Values (NPV) formula ……………………………………

39

Figure 9.

Net Present Values (NPV) Calculations to assess the Probability of
Regulatory Success (PRS) of a non-orphan drug………………………

40

Figure 10.

New drug Research and Development Expenditure ……………………

45

Figure 11.

Conceptual Framework for Probability of Regulatory Success (PRS) of
Orphan Drugs ………………………………………………………..

58

Figure 12.

Data Abstraction: PRISMA Flow Chart in Meta-analysis………………

67

Figure 13.

Meta-Analysis in Quantitative Research ………………………………

69

Figure 14.

Steps in Meta-Analysis…………………………………………………

71

Figure 15.

Effect Sizes and Study Weights in Comprehensive Meta-analysis
(CMA) v. 3.0 software…………………………………………………

78

Figure 16.

IBMÔ SPSSÒ Regression Software ……………………………………

80

Figure 17.

AODI Validation and Standardization…………………………………

91

Figure 18.

Revised Conceptual Framework for Probability of Regulatory Success
of Orphan Drugs ………….……………………………………………

Figure 19.

105

Revised Algorithm for Assessing the Probability of Regulatory Success
of Orphan Drugs ………………………………………………………… 106

Figure 20.

Calculation of Probability of Regulatory Success of Orphan and NonOrphan Drugs using validated Algorithm. ………………………………

107

xi
ABSTRACT

Meta-analysis to identify and evaluate factors associated with regulatory approval of
Orphan Drugs (OD) to develop an algorithm for predicting regulatory approval (success)
and to develop a standardized tool to improve orphan drug portfolio decision-making.

Background and Purpose of the Study: Developed an algorithm (AODI) for predicting probability
of regulatory success (PRS) for new orphan drugs after phase II testing has been conducted with
the objective of providing a tool to improve drug portfolio decision-making. Methods: Examined
132 studies from recent publications (2005 onwards). Data on safety, efficacy, operational, market,
and company characteristics were obtained from public sources. Meta-analysis and metaregressions were used to provide an unbiased approach to assess overall predictability and to
identify the most important individual predictors. Results: Found that a simple three-factor model
(disease prevalence, clinical trial duration and clinical trial participation) had high specificity for
predicting regulatory approval (success). Conclusion: smaller clinical trial participation, shorter
clinical trials duration and lower rare disease prevalence were found to be highly associated with
the Probability of Regulatory Success (PRS) of orphan drugs.

Keywords: meta-analysis, meta-regression, orphan drugs, probability, regulatory success,
regulatory approval, predictors, clinical trials, participation, duration, prevalence, research and
development, regulatory assessment, policy, legislations
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CHAPTER I
INTRODUCTION

Problem Background
In general, an orphan or rare disease is any pathology or condition that affects a
small percentage of the population (Wastfelt et al., 2006). Most of the known rare diseases
are genetic, and therefore, are present throughout the entire life of an affected individual.
Many appear early in life and about 30% of children with rare diseases die before the age
of 5 years (Wastfelt et al., 2006). There is no single cut-off number that has been
universally agreed upon for which a disease is classified as rare. For instance, in the United
States (US) the Orphan Drug Act (ODA) defines a rare disease as any disease or condition
that affects less than 200 000 persons in the United States (US), while in Japan for example
a rare disease is defined as one that affects fewer than 50 000 patients. The European
Commission on Public Health, on the other hand, defines rare diseases as those which are
life-threatening or chronically debilitating and are of such low prevalence (1 in 2000
people) that special combined efforts are needed to address them. Additionally, a disease
considered rare in one part of the world, or in a particular group of people, could be a
common disease in another. The incidence of an individual rare disease may be small
however, cumulatively, there are 7,000 known rare diseases that affect about 25 million
Americans, or nearly 10% of the US population (Hemphill, 2009). Since the definition of
rare diseases refer to treatment availability, resource scarcity and disease severity, rare
diseases are also commonly referred to as orphan diseases, especially after the orphan drug
movement that began in the United States in 1983. Consequently, the US Orphan Drug Act
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of 1983 includes both rare diseases and any non-rare diseases for which there is no
reasonable expectation that the cost of developing and making available a drug for such a
disease in the United States (US) can potentially be recovered from sales of that drug in
the United States (US). About 7,000 rare diseases have been identified, and a list is
maintained by the Office of Rare Diseases (ORD) at the National Institutes of Health
(NIH). While some of the listed rare diseases are well-known (e.g. cystic fibrosis,
Huntington’s disease), a majority are less familiar with several disease having patient
populations of fewer than a hundred, these are called ultra-rare. Approximately 250 new
rare diseases and conditions are identified and described each year (Aarti, 2009). The US
Orphan Drug Act (ODA) went into effect to encourage the research and development of
orphan drugs to treat rare diseases. The Orphan Drug Act (ODA) evolved in response to
the small number of orphan drugs (OD) that were approved in the US in the years prior to
the approval of the Orphan Drug Act (ODA) (Mullard, 2012). The development process
for orphan drugs is technically the same as that for any other drug developed to treat any
disease: very expensive and time consuming (Schieppati et al., 2008). It’s key to determine
which factors actually contribute the successful approval of orphan drugs (OD).
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Problem Statement
Pharmaceutical industry drug development portfolios vary in scope and range. For
each company, however the objective of improving the regulatory success rate of their
applications is paramount. Orphan drugs are called orphan not only because it impacts a
small number of patients in the overall population, but also their name is appropriate as a
small number of companies feel less confident in investing in their development (DiMasi
et al., 2003). Understanding the key factors associated with regulatory approval (regulatory
success) of orphan drugs (OD) may assist pharmaceutical companies in developing more
efficient regulatory strategies and predict with a high level of certainty the likelihood of
orphan drugs reaching the market.

Purpose of the Study
The purpose of this study is to identify and evaluate factors associated with
regulatory approval of Orphan Drug (OD) in addition to systematizing those components
in a mathematical formula to determine with a certain degree, the probability of regulatory
success and implement it when assessing the risk in developing, registering and marketing
orphan drugs.
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Research Questions
Is it possible to identify, compare and evaluate the relevant factors associated with
orphan drug approval and systematize a workable model that is applicable to the
pharmaceutical industry to assess the risk of developing and registering orphan drugs?
I.

Do shorter clinical trials increase the probability of regulatory approval
(success) of orphan drugs (OD)?

II.

Do smaller clinical trials increase the probability of regulatory approval
(success) of orphan drugs (OD)?

III.

Does prevalence of the disease increase the probability of regulatory
approval (success) of orphan drugs?

Research Hypotheses
RQ1: Is it possible to identify the relevant factors associated with the probability of
regulatory success of orphan drugs (OD)?
H1a: Yes, it is possible
H1b: No, it is not possible

RQ2: Is it possible to compare the relevant factors associated with the probability
of regulatory success of orphan drugs (OD)?
H2a: Yes, it is possible
H2b: No, it is not possible
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RQ3: Is it possible to evaluate the relevant factors associated with the probability
of regulatory success of orphan drugs (OD)?
H3a: Yes, it is possible
H3b: No, it is not possible

RQ4: Is it possible to develop an algorithm for predicting the probability of
regulatory success of orphan drugs (OD)?
H4a: Yes, it is possible
H4b: No, it is not possible

RQ4.1: Do shorter clinical trials increase the probability of regulatory
success of orphan drugs (OD)?
H4.1a: Shorter clinical trials increase the PRS for OD.
H4.1b: shorter clinical trials decrease the PRS for OD.

RQ4.2: Do smaller clinical trials increase the probability of regulatory
success of orphan drugs (OD)?
H4.2a: Smaller clinical trials increase the PRS for OD.
H4.2b: Smaller clinical trials decrease the PRS for OD.
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RQ4.3: Does a lower number of patients worldwide affected by a rare
disease (prevalence) increase the probability of regulatory success of
orphan drugs (OD)?
H4.3a: Lower prevalence increase PRS for OD.
H4.3b: Lower prevalence decrease PRS for OD.
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Significance of the Study
Rare diseases have become a public heath priority in the United States (Cheung et
al., 2004). Healthcare professionals lack of proper training and awareness to identify,
diagnose and treat rare diseases (Sharma et al., 2010). There is also delay to a correct
diagnosis, lack of quality information and scientific knowledge, inequities and difficulties
in access to treatment and care making rare diseases a matter of public health in the US
(Schieppati et al., 2008). Scholars have reported in early 2000 that the pharmaceutical
industry is not incentivized to invest in research and development for orphan drugs, causing
limited industry involvement and leaving millions of patients in the US and around the
world with no treatments for their diseases (Grabowski, 2003). According to the Orphan
Drug Act (ODA), an orphan drug (OD) is a pharmaceutical agent that has been developed
specifically to treat a rare medical condition (21 CRF § 316). Orphan drugs can affect both
the quality and length patients’ lives (Sharma et al., 2010). Effective orphan drugs can
extend and improve patients’ lives. Prior to the Orphan Drug Act (ODA), the number of
annual deaths from rare diseases were growing at a slightly higher rate than that from other
diseases (2.0 percent and 1.3 percent, respectively) (Lichtenberg, 2001). In the 10 years
following the Orphan Drug Act (ODA), the number of annual deaths from rare diseases
declined at a rate of 3.1 percent, while the annual number of deaths from other diseases
continued to grow at a rate of 1.2 percent (Lichtenberg, 2001).

Orphan drugs have also the potential to generate large improvements in patients’
lives because rare diseases typically have few, if any, effective treatments available
(Cheung et al., 2004). According to the National Office of Rare Diseases Research
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(NORD) only 289 of the 7,000 identified rare diseases have one treatment option. That
means, only four percent of recognized rare diseases have an available treatment
(Schieppati et al., 2008).

A recent survey, conducted by the biotechnology company Shire, found that rare
diseases take a significant emotional toll on patients. Patients reported suffering from
isolation from friends and/or family (65%), depression (75%), anxiety and stress (86%)
(The Shire Report, 2013). Patients often have to travel long distances to receive treatment.
On average, it takes 7.6 years for rare-disease patient in the United States (US) to receive
an accurate diagnosis, and patients may see up to four primary care doctors and four
specialists before receiving an accurate diagnosis (The Shire Report, 2013). Orphan drugs
(OD) can reduce the emotional toll patients and caregivers face by relieving symptoms and
decreasing the burden of inferior treatment options. These improvements may help reduce
feelings of depression, isolation, anxiety, and stress patients and caregivers often
experience (Sharma et al., 2010).

Orphan drugs (OD) can also deliver a broad set of economic benefits beyond the
increased well-being of patients and caregivers (Sharma et al., 2010). Orphan drugs may
increase patients’ ability to work, reduce net medical expenditures, and lower the total
government spending (Schieppati et al., 2008). Those suffering from chronic disease tend
to be less productive at work, either through increased absenteeism or limitations imposed
by their disease (Schieppati et al., 2008). Patients with rare diseases often find it difficult
to remain at their jobs due to the symptoms of their disease (The Shire Report, 2013). As
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a result, treatments that help patients to return to work, provide childcare, or participate in
other activities may generate benefits beyond improved health.
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Operational Definitions

Algorithm: A procedure or formula for solving a problem based on conducting specific
steps or actions

Approval: Authorization by the Food and Drug Administration (FDA) for the marketing of
a drug (under a New Drug Application), medical device (under a Premarket Approval
Application), or biological product (under a Biologics Licensing Agreement)

Benefit: A positive or valued outcome of an action or event.

Biologics Licensing Application (LA): Form used by bio-pharmaceutical companies to
request FDA approval to market a new biologic product in the United States (US) based
on information about its safety, effectiveness and other requirements.

Clinical trial: A medical study involving human participants that follows a defined protocol
to answer specified questions, for example, about the safety and efficacy of a medical
product.

a. Phase I trials initiate the study of candidate drugs in humans. Such trials
typically assess the safety and tolerability of a drug, routes of administration
and safe dose ranges, and the way the body processes the drug (e.g., how it is
absorbed, distributed, metabolized, and excreted). They usually involve less
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than 100 individuals, often-healthy volunteers.

b. Phase II trials continue the assessment of a drug’s safety and dosing but also
begin to test efficacy in people with the target disease. These studies may
include a range of controls on potential bias, including use of a control group
that receives standard treatment or a placebo, the random assignment of
research participants to the experimental and control groups, and the
concealment (blinding) from participants and researchers of a participant’s
assignment.

c. Phase III trials are expanded investigations of safety and efficacy that are
intended to allow a fuller assessment of a drug’s benefits to provide information
sufficient to prepare labeling or instructions for the use of the drug. These
studies may involve thousands of research participants and multiple sites.

d. Phase IV studies occur after a product is approved for marketing and are highly
variable in their design. They are sometimes required by FDA but may be
voluntarily undertaken by pharmaceutical companies. They are typically
intended to provide further information about outcomes in clinical practice, e.g.,
in broader populations or over longer periods than studied in the trials used to
support FDA approval.
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Data exclusivity: A period of time during which pharmaceutical companies of innovative
drugs have the exclusive use of the safety and effectiveness data they submitted to obtain
FDA approval.

Drugs: As defined in 21 USC 321(g)(1): “(A) articles recognized in the official United
States Pharmacopoeia, official Homoeopathic Pharmacopoeia of the United States, or
official National Formulary, or any supplement to any of them; and (B) articles intended
for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in man or
other animals; and (C) articles (other than food) intended to affect the structure or any
function of the body of man or other animals; and (D) articles intended for use as a
component of any article specified in clause (A), (B), or (C).”

Effectiveness: The achievement of desired results in actual clinical practice.

Efficacy: The achievement of desired results in controlled clinical studies.

Market exclusivity: As provided for by the Orphan Drug Act, a 7-year period during which
a pharmaceutical company has exclusive rights to market the drug.

Meta-Analysis: An objective and quantitative methodology for synthesizing previous
studies and research on a particular topic into an overall finding.

New Drug Application (NDA): Form used by pharmaceutical companies to request FDA
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approval to market a new pharmaceutical drug in the United States (US) based on
information about its safety and effectiveness and other requirements

Post-market activities: Evaluations, activities, and decisions that occur after regulatory
approval, clearance, or registration of a medical product for marketing.

Preclinical studies: Investigations of toxicity, pharmacological activity, and other
characteristics of a promising drug candidate that occurs prior to research with human
participants.

Prevalence: The number of diagnosed cases of a particular condition or disease existing in
a specified population at a given time. It is distinct from incidence, which is the number of
new cases of the disease arising in the population over a given time period.

Portfolio decision-making: Act or process of deciding after careful evaluation of factors on
whether or not a drug should move forward in the pipeline.

Probability of Regulatory Success (PRS): Likelihood that a government body or health
authority will grant drug approval

Rare disease: In the Orphan Drug Act, a disease or condition that affects fewer than
200,000 people in the United States (US).
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Regulatory approval: A process conducted by a government body or health authority in a
country resulting in pharmaceutical product registration and a valid license for
commercialization

Regulatory science: The development and use of new tools, standards and approaches to
more efficiently develop products and to more effectively evaluate product safety, efficacy
and quality.

Risk: A potential harm or the potential for an action or event to cause harm.

Safety: There is reasonable assurance that a drug is safe when it can be determined, based
upon valid scientific evidence, that the probable benefits to health from use of the device
for its intended uses and conditions of use, when accompanied by adequate directions and
warnings against unsafe use, outweigh any probable risks.

Standardized tool: A tool designed in a way that the results and interpretation is consistent.

Orphan drugs: Any “pharmaceutical agent” use to treat or diagnose a rare disease.
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CHAPTER II
LITERATURE REVIEW

Rare Disease Definition and Prevalence
A rare disease can also be referred as orphan disease (Wästfelt, Fadeel & Henter,
2006). It is any type of disease that affects a small percentage of the population (21 CFR §
316). Rare disease can be defined by the number of people living with the disease, etiology,
mobility, survival rate or incidence rate however the orphan drug acts define it as “a lifethreatening or chronically debilitating disease that affects less than 200,000 people” (21
CFR § 316). Although rare disease affects only a small percentage of the population, the
combined number of patients is large. This is also known as the paradox of rare diseases
(Wästfelt et al, 2006). The incidence of an individual rare disease is very small; however
collectively there are over 7,000 known rare diseases that affect approximately 30 million

Rare Disease: Prevalence

Americans: nearly 10% of the US population (Sharma, Jacob, Tandon & Kumar, 2010)
10

Although rare diseases affect only a small percentage of the
Figure 1. Paradox of Rare Diseases (Sharma, Jacob, Tandon & Kumar, 2010).
whole population, the combined number of patients is large
(Sharma et al., 2010).
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Rare Disease Characteristics
•

Chronic progressive, degenerative and life threating (Wästfelt et al, 2006).

•

Patient’s quality of life is compromised by lack or loss of autonomy (Wästfelt et al,
2006).

•

High level of pain and suffering for the patient and family members (Sharma et al.,
2010).

•

No existing effective cure or treatment (Sharma et al., 2010).

•

75% of rare diseases affect children and 30% of patients die before age of 5 (Wästfelt
et al, 2006).

•

80% have been identified of genetics origins (Wästfelt et al, 2006)

Orphan Drug Definition and Classification
An orphan drug is “any pharmaceutical agent that has been developed specifically
to treat a rare medical condition” (21 CFR § 316). Orphan drugs can be classified into two
groups according to their patent status. According to Hutt and Merrill, orphan drugs can be
classified in two types:
Type I drugs ineligible for any patent rights as these drugs are actually available in
the public domain and are not consider novel (a patent requirement). These drugs are
already known to treat certain diseases or conditions but the prohibitive cost of developing
and receiving regulatory approval for the drugs prevents these treatments from being
produced or put on the market by the private sector (Hutt & Merrill, 1991).
Type II drugs that would be patentable, but they do not exist because there has been
an absence of research into such treatments (Hutt & Merrill, 1991). Simply, the number of
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people who would require the drug is either so small as to be insignificant or such a group
does not constitute a major market segment for pharmaceutical companies. It is important
to note however that the problem of orphan drugs type II must be understood separately
from the problem of insufficient access to medicine and treatments that already exist for
certain diseases. Orphan drugs type II refers to the problem of potential treatments that
have not yet been developed and do not exist.

United States Patent and Trademarks Office (US PTO)
The United States Patent and Trademark Office (US PTO) is first federal
organization involved in the orphan drug registration and approval process. The US PTO
is an agency in the US Department of Commerce that issues patents to investors for their
inventions, and trademark registration for product and intellectual property identification
(21 CFR §393). The USPTO mission is to promote “industrial and technological progress
in the United states and strengthen the national economy” in order to fulfill objectives
outlined in the United States constitution (21 CFR §393).
It is important to define the term “Patent”. A patent is a set of exclusive rights
granted by a sovereign state, in this case the United States Patent and Trademark Office
(US PTO), to an inventor for a limited period of time in exchange for detailed public
disclosure of an invention (World Intellectual Property Organization definitions, 2008).
“An invention is a solution to a specific technological problem and is a product” (WIPO
definitions, 2008). Patents are a form of intellectual property (WIPO definitions, 2008).
The procedure for granting patents, requirements placed on the patentee, and the extent of
the exclusive rights is overseen by the United States Patent and Trademark Office
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(USPTO). Typically, a granted patent application must include one or more claims that
define the invention. A patent may include many claims, each of which defines a specific
property right. These claims must meet relevant patentability requirements: novelty,
usefulness, and non-obviousness (WIPO definitions, 2008). The exclusive right granted to
a patentee in the United States is the right to prevent others from commercially making,
using, selling, importing, or distributing a patented invention without permission (WIPO
definitions, 2008). Under the World Trade Organization (WTO) agreement on trade-related
aspects of Intellectual Property Rights (IPR), patents should be available in WTO member
states for any invention, in all fields of technology, and the term of protection available
should be a minimum of twenty years (WIPO, 2008).
To obtain a patent, an application must be filed at the USPTO with the jurisdiction
to grant a patent in the geographic area over which coverage is required (WIPO, 2008).
Once the patent specification complies with the laws of the office concerned, a patent may
be granted for the invention described and claimed by the specification (WIPO, 2008). In
most countries, both natural persons and corporate entities may apply for a patent. In the
United States, however, only the inventor may apply for a patent although it may be
assigned to a corporate entity subsequently and inventors may be required to assign
inventions to their employers under an employment contract (Lemley & Shapiro, 2005).
The inventors become the proprietors of the patent when and if it is granted. If a patent is
granted to more than one proprietor, the laws of the country in question and any agreement
between the proprietors may affect the extent to which each proprietor can exploit the
patent (WIPO, 2008).
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Patents provide incentives for economically efficient research and development
(R&D) (Lemley & Shapiro, 2005). A study conducted annually by the Patent Intelligence
for Policy Support (PIPS) shows that the 2,000 largest global companies invested more
than 430 billion dollars in 2008 in their research and development departments (Lemley &
Shapiro, 2005). Supporters of patents argue that without patent protection, research and
development spending would be significantly less or eliminated altogether, limiting the
possibility of technological advances and breakthroughs (Lemley & Shapiro, 2005).
Corporations would be much more conservative about the research and development
investments they made, as third parties would be free to exploit any developments (Lemley
& Shapiro, 2005).

United States Food and Drug Administration (US FDA)
The second federal organization involved in regulatory approval of orphan drugs
(OD) is the Food and Drug Administration (FDA). The FDA was created in 1820 and it is
the oldest federal agency in the United States. The FDA is responsible for “protecting and
promoting public health through the regulation and supervision of food safety, tobacco
products, dietary supplements, prescription and over the counter pharmaceutical drugs
(medications), vaccines, biopharmaceuticals, blood transfusion, medical devices,
electromagnetic radiation emitting devices (ERED) and veterinary products” (21 CFR §
393). The agency has over 20 offices but the Center for Drug Evaluation and Research
(CDER) is considered the main department where drugs approval takes place (21 CFR §
393). The mission of FDA's Center for Drug Evaluation and Research (CDER) is to ensure
that drugs marketed in the United States are safe and effective (21 CFR § 393). CDER does
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not test drugs, although the Center's Office of Testing and Research does conduct limited
research in the areas of drug quality, safety, and effectiveness (21 CFR § 393). CDER is
the largest center at the FDA. It has responsibility for both prescription and nonprescription
(Over-The-Counter also known as OTC) drugs. Pharmaceutical companies submit a New
Drug Application (NDA) to introduce a new drug product into the U.S. Market (21 CFR §
393). It is the responsibility of the pharmaceutical company seeking to market a drug to
test it and submit evidence that it is safe and effective (21 CFR § 393). A team of CDER
physicians, statisticians, chemists, pharmacologists, and other scientists reviews the
application containing the data and proposed labeling (21 CFR § 393).

The office of Regulatory Affairs is also considered an important department within
the FDA conducting the vast majority of the FDA's work in the field (21 FDAC § 393),
however is the Office of Special Medical Program the one that oversees the implementation
of the orphan products provisions of the Federal Food, Drug and Cosmetic Act (21 FDAC
§ 393). The FDA Office of Orphan Products Development (OOPD) is dedicated to advance
the evaluation and development of products (drugs, biologics, devices, or medical foods)
that demonstrate promise for the diagnosis and/or treatment of rare diseases or conditions
(21 FDAC § 393). In order to fulfilling that task, OOPD evaluates scientific and clinical
data submissions from pharmaceutical companies to identify and designate products as
promising for rare diseases and to further advance scientific development of such
promising medical products (21 FDAC § 393).In addition, the OOPD works on rare
disease issues along with medical and research communities, professional organizations,
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academia, governmental agencies, industry, and rare disease patient groups (21 FDAC §
393).
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The Center for Drug Evaluation and Research (CDER) and the Center for Biologics
Evaluation and Research (CBER) have regulatory responsibility, including pre-market
review and continuing oversight over products. They are responsible to ensure that
products are safe and effective prior granting regulatory approval for marketing.
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The Office of Orphan Products Development (OOPD) is task to advance the
evaluation and development of orphan products (drugs, biologics or medical devices) that
demonstrate promise for the diagnosis or treatment of rare diseases.

The OOPD oversees two programs: a) the Orphan Drug Designation program which
provides orphan status to drugs and biologics which are intended for the safe and effective
treatment, diagnosis or prevention of rare diseases that affect fewer than 200,000 people in
the U.S., or that affect more than 200,000 persons but are not expected to recover the costs
of developing and marketing a treatment drug (21 FDAC § 393) and b) the Humanitarian
Use Device (HUD) program, who designates a device intended to benefit patients by
treating or diagnosing a disease or condition that affects fewer than 4,000 individuals in
the United States per year as per the Orphan Drug Act (ODA) (21 CFR § 316).

The United States Orphan Drug Act (ODA)
The Orphan Drug Act (ODA) is a law passed in the United States to facilitate
development of orphan drugs which affect small numbers of individuals residing in the
United States. (Orphan Drug Act, 1983). The Orphan Drug Act (ODA) was passed in large
part due to the lobbying efforts of patient’s groups and the national Organization for Rare
Disorders (NORDs) and many other patients groups frustrated at the lack of drugs approved
to treat rare diseases (Cheung, Cohen & Illingworth, 2004). In 1983 the FDA was
empowered by the United States Congress to enforce the Orphan Drug Act. During the
decade of 1970s, only 10 drugs were marketed for rare diseases indications and by 1982,
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36 drugs had ever been approved for the treatment of rare diseases (House of representative
Subcommittee Report, 1982). It was found that pharmaceutical companies at times
possessed drug with potential benefits for patients suffering from rare diseases however
these drugs were not patentable, or their clinical trials were too costly (Cheung, Cohen &
Illingworth, 2004). This evidence motivated lobbying efforts of patient groups to pass
orphan drug legislation. The ODA includes a number of incentives so pharmaceutical
companies can develop orphan drugs and provide access to more than 30 million people in
the US suffering from rare diseases (Cheung et al., 2004).

ODA was signed into law on January 4th, 1983; making the United States the first
country in the world to provide incentives for developing treatments for rare diseases
(H.R.5238). “The cost of discovering and developing a new drug is often staggering. By
definition, an orphan drug is one that treats a disease that affects 200,000 or fewer
individuals and, from an economic perspective, groups that small do not now justify the
kind of research expenditures those companies must make. The bill that I am signing today
helps to cure that problem and consequently, we hope, some of the diseases as well. The
bill provides incentives for the private sector to develop drugs to treat these rare diseases”
(Reagan, 1983). Since then, Australia, Japan, and the European Union have instituted
provisions similar to the ODA to support the development of orphan drugs in their
respective countries (Cheung et al., 2004).
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Figure 3. Orphan Drug Legislation Status Worldwide (Cheung et al., 2004).

Japan has extended his orphan drug definition to include medical devices, so all
medical device used to treat or diagnosed a rare disease has also protection under the law.
All four legislation provides market exclusivity of 7 to 10 years with the exemption of
Australia. Market exclusivity is a big incentive for any pharmaceutical companies around
the world. It is important to highlight the differences between major legislations in table
below specifically in the areas of tax credit, research and development grants and
regulatory fee exemption as each market have distinct law and regulation of drug review
and approval. Finally, it takes approximately 6-8month after regulatory submission to
received orphan drug designation in all markets apart from the European Union (EU) which
takes 18 months or more after regulatory submission.
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Orphan Drug Legislation in US and major
Table I. Orphan Drug Legislation in US and major markets (Cheung, 2004).
markets
continue
US (1983)

EU (2000)

Japan (1993)

Australia(1997)

Scope

Drugs

Drugs

Drugs and devices

Drugs

Designation criteria

< 200,000
>200,000 but not
commercially viable

< 5/10,000
No alternative treatment
Unlikely to get financial
return

<50,000
Serious and no
alternative treatment.
Prove high efficacy,
safety and development
feasibility.

< 2,000
Not commercially viable

Market exclusivity

7 years

10 years

10 years

No

Protocol assistance

Yes

Yes

On request

On request

Priority review

Yes (depends on data
and medical need)

Centralized

Yes

Yes

Tax credit

Up to 50% of clinical
studies

Member state specific

6% of clinical and non
clinical studies

No

R&D grants

Yes

Member state specific

Yes

No

Exemption of
regulatory fee

Yes

Reduced

No

Yes

Timeline

6-8motnhs

> 18 months

10 months

Not clear.

Table 1. Orphan drug legislation in US and major markets.
Source: Cheung, 2004)

Orphan Drug Act Incentives
The Orphan Drug Act (ODA) contains a number of provisions designed to
encourage investment in orphan drug research and increase the number of drugs available
for patients affected by a rare disease (Cheung et al., 2004). Pharmaceutical companies that
developed and successfully register orphan drugs in the US receive: 1) priority review 2)
protocol assistance 3) market exclusivity 4) tax credits 5) regulatory fees exemptions and
7) research and development grants. (H.R.5238)

1. Priority review is an orphan drug act incentive, where the time that the FDA
takes to review and successfully approve an orphan drug is shorter compared to
non-orphan drugs (Hutt & Merrill, 1991). An estimated time for orphan drug
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approval is 6-8 months in contrast to non- orphan drugs that require 18- 20
months (Hutt & Merrill, 1991).

2. Market exclusivity is another orphan drug act incentive and represents an
economic reward. It provides pharmaceuticals companies with a monopoly over
the drug. This incentive is critical to the success of pharmaceutical companies
in both profitability and recuperating invested capital (Hutt & Merrill, 1991).
Market exclusivity for orphan drugs is very different from non-orphan drugs as
the first provides 7 years exclusivity and patent law protection begins once the
drug is approved (Hutt & Merrill, 1991).

3. Research and development grants have been reported to be good motivators for
pharmaceutical companies when added to the pool of incentives offer by the
Orphan Drug Act (Cheung, et al., 2004). Pharmaceutical companies are aware
of the risks in investing on orphan drug development. The most obvious risk in
drug development is that, despite a long and costly development process, most
new drugs candidates will not reach the market (Sharma et al., 2010). Only
fractions of one percent of the new drugs that are synthesized and examined in
pre-clinical studies make it into human testing. Of these, only 20% of the new
drugs entering clinical trials survive development and FDA approval process
(Sharma et al., 2010). As part of the ODA of 1983, Congress recognized a need
to fund clinical research that test promising new therapies for rare diseases. The
FDA and the Office of Orphan Products Development Grants Program (OOPD)
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awards grants for clinical trials only for products that have received or could
potentially receive orphan status designation (Cheung, et al., 2004). The drug
program includes the pre-market review of human drugs and biological
products in order to ensure their safety and efficacy and the post marketing
monitoring of drug experience (Cote, 2011).

4. Orphan Drug Tax Credit (ODTC) allows pharmaceutical companies to claim a
tax credit for up to 50 percent of qualified clinical testing expenses (H.R.5238).
Clinical testing costs are a subset of the total cost to bring a new drug to market
(Cote, 2011). Qualified expenses for the orphan drug tax credit include human
clinical testing costs incurred between orphan designation and drug approval
(Cote, 2011). The ODTC also covers expenses related to human clinical testing
conducted outside the United States only if an insufficient population of test
participants exists domestically (Cote, 2011). Qualified expenses for the ODTC
cannot be used toward the research (R&D) tax credit (H.R. 5238). For rare
diseases, clinical trial costs alone can total thousands of dollars per person
diagnosed with the disease (Sharma et al., 2010). Between 1996 and 2011, the
amount of ODTC awarded to orphan drug pharmaceutical companies increased
from $31 million to over $750 million (Hay et al., 2014)

For a drug to qualify for provisions contained in the ODA, it must receive an orphan
drug designation from the FDA (21CFR §316). Pharmaceutical companies may apply for
orphan drug designation at any time before filing a New Drug Application (NDA) or
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Biological License Application (BLA) (Hutt & Merrill, 1991). The Office of Orphan
Products Development within the FDA reviews applications for orphan drug designation
and determines if a drug is eligible to receive the Orphan Drug Tax Credit (ODTC) and
other orphan drug act incentives (21 CFR §316). Receiving an orphan drug designation
does not change the market approval process nor does it imply that the drug will one day
reach the marketplace (Villarreal, 2001).

Figure 4. Orphan Drug Designation Process (FDA database, 2015 available at
https://www.fda.gov/forindustry/developingproductsforrarediseasesconditions/howtoappl
yfororphanproductdesignation/default.htm)
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The average review time for an orphan drug designation is 90 days, and between
60 percent and 70 percent of all applications result in drugs receiving orphan drug status
(Hutt & Merrill, 1991). A drug can only receive orphan drug designation once it has been
determined to diagnose or treat a rare disease (21 CFR §316). Each orphan drug is approved
for specific use (21 CFR §316). Each of these uses is called an indication and when granting
market approval, the FDA only authorizes a drug for its approved indication (21 CFR
§316). It is possible for pharmaceutical companies to obtain a new orphan designation for
an existing drug only if a new indication or use is found (21 CFR §316). This encourages
pharmaceutical companies to seek new ways for existing drugs to be used to benefit
patients with rare diseases (Hutt & Merrill, 1991).
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Impact of Orphan Drugs on Orphan Drug Designations
The Orphan Drug Act (ODA) was signed into law in early 1983 and since it had a
significant impact on public health. In the 34 years since this pioneering law was passed,
more than 500 drugs have become available to patients with rare diseases in the United
States, whereas in the 8–10 years prior to the orphan drug legislation, only 1 treatment per
year for rare diseases was approved by the FDA and brought to the market.

Figure 5. FDA Orphan Drug Approvals 1983-2017 (FDA database, 2017 available at
https://www.fda.gov/ForIndustry/DevelopingProductsforRareDiseasesConditions/Events/
ucm598211.htm)

Post ODA, there has been a dramatic increase in the number of new orphan drugs
brought to market (FDA database, 2015). The number of new orphan drugs in the
development pipeline has increased rapidly as well. “The enactment of the Orphan Drug
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Act in 1983 has proved to be a very successful venture in public policy, focusing private
dollars and intellect on these vexing and often fatal diseases” (Wyden, 1994). Incentives
of the ODA have played an important role in the increase in orphan drug manufacturing
over the last 30 years (Sharma et al., 2010). Since 1983, 201 new orphan drugs have been
brought to market, in part, due to the ODA (FDA database, 2017). The increase in drug
innovation and development has been especially strong in recent years; with 50 new orphan
drugs approved in 2017 (FDA database, 2017).

The ODA is also used to assist pharmaceutical companies in the re-purposing of
existing drugs for the treatment of rare diseases (Villarreal, 2015). A total, 486 orphan
products have been approved since ODA was enactment in 1983 (FDA database, 2017).
Re-purposing strategy includes a mix of more effective formulations, new indications,
dosages, sources of supply, and other changes that have illustrated clinical superiority
(FDA database, 2015). While no all approvals represent a new orphan drug, these approvals
have the potential to improve outcomes for the patients they were designed to treat. The
development pipeline for new orphan drugs also continues to increase. Between 2004 and
2017, the FDA has awarded nearly 2,000 orphan designations (FDA database, 2017).
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Risk Associated with Orphan Drug (OD) Research and Development (R&D)
The two most significant market barriers to the development of new orphan drugs
are 1) high development costs and 2) limited patient populations (Sharma, et al., 2010).
Each new orphan drug requires a substantial investment in research and development with
limited chance the drug will make it to market (Hutt & Merrill, 1991). The small pool of
potential patients further reduces the ability of a pharmaceuticals company to recover their
research investment (Hutt & Merrill, 1991). Drug development costs are high in part
because relatively few drugs make it through the development process, by the time drugs
enter the preclinical phase of testing, only 1 out of 5 remaining drugs will receive market
approval (Hutt & Merrill, 1991). The total research and development cost to produce a
single approved drug includes not only the cost to develop the successful approved drug,
but also the cost of the unsuccessful drugs (Hutt & Merrill, 1991).

Before the ODA came into effect, academic research began to show rising drug
development costs (Hutt & Merrill, 1991). In the 1970s, the total cost of bringing a new
drug to market was $182 million (in 2012 dollars), and by the 1980s, that number had risen
to $205 million (in 2012 dollars) (Meekings, Williams & Arrowsmith, 2012). Current
estimates of the total cost to bring a new drug to market are $1.5 billion (in 2012 dollars)
(Meekings, 2012). The total cost of bringing a new drug to market includes: out-of-pocket
expenses, the cost of failures and capital cost (Sharma, et al., 2010).
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After a drug receives market approval, the pharmaceutical company can begin to
recover its investment in the discovery and research process (Sharma, et al., 2010). For
orphan drugs, the opportunity is diminished due to the limited pool of potential patients,
which is one reason many pharmaceutical companies find it difficult to justify the
investment required to develop treatments for rare diseases (Sharma, et al., 2010).
According to the ODA, orphan drugs are designed to treat conditions that exist in less than
200,000 patients in the United States, and for many rare diseases, the number of cases may
be far less than 200,000 (DiMasi, Hansen & Grabowski, 1991).

In addition to high costs and other market-based disincentives, significant
regulatory barriers existed (Sharma, et al., 2010). A robust and comprehensive FDA
approval process is important to ensure drugs reaching the market are safe and effective,
but it also increases the timeline and cost of drug development (21 CFR §316). It takes an
average of 12.5 years and $1.5 billion (in 2012 dollars) to bring a new drug from the
preclinical stage through FDA regulatory approval (Cote, 2012). For potential
pharmaceutical companies of new orphan drugs, who have a limited patient pool from
which to recover these costs, the incentives available under the ODA can be a factor in
determining which investments to pursue (DiMasi, et al., 1991).

Once a new potential drug is discovered, it enters preclinical testing during which
initial safety assessments take place in a laboratory (21 CFR §316). Before being tested in
humans the pharmaceutical company must submit an Investigational New Drug
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Application (IND) to the FDA. Once the FDA approves the IND, clinical trials can begin
(Hay, Thomas, Craighead, Economides & Rosenthal, 2014).

Clinical testing culminates in Phase III with randomized trials in human volunteers
(21 CFR §316). This phase can be particularly challenging for pharmaceutical companies
of orphan drugs who may struggle to find the necessary number of trial participants to
achieve statistically significant results (Sharma, et al., 2010). If a drug successfully
completes each clinical trial phase, the pharmaceutical company can submit a New Drug
Application (NDA) or Biologic License Application (BLA) to the FDA for market
approval (Cheung, et al., 2004). If the FDA grants market approval, the treatment becomes
available to patients. Once a drug becomes available to patients, the costs of development
may not end. The FDA can require drug developers to participate in Phase IV post-market
monitoring, which may further increase the overall costs of drug development (DiMasi et
al., 1991).

The span of time between new drug discovery and market approval means there
could be relatively few years remaining of patent protection by the time the drug reaches
the market (Cheung, et al., 2004). This is particularly challenging for pharmaceutical
companies who already face a limited market from which to recover their research costs.
As a result, pharmaceuticals companies can be discouraged from investing in drugs with a
potentially limited market value (Meekings et al., 2012). Since the enactment of the Orphan
Drug Act (ODA) in 1983, Congress has repeatedly amended the ODA to include additional
incentives and support for orphan drug development (Villarreal, 2015). Some changes have
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simply improved the clarity and focus of the provisions, such as the 1984 amendments to
the ODA, which defined rare diseases as affecting fewer than 200,000 patients in the
United States (Villarreal, 2015). Others have strengthened the original Act, such as by
extending market exclusivity to patentable, as well as un-patentable products (Meekings et
al., 2012). Congress waived certain fees for orphan drug developers in 1992, and in 1997
permanently extended the ODTC (Villarreal, 2015). According to the FDA, fee waivers
can total $2 million, which can offer significant assistance, especially for small
pharmaceutical companies (Meekings et al., 2012). Research and development (R&D) of
new orphan drugs is not concentrated among a few pharmaceutical companies, but is
broadly distributed throughout the industry (Cote, 2011). Between 2004 and 2014, 65
separate companies received market approval for at least one new orphan drug. For nearly
a third of those companies, approval was for their first successful drug brought to market,
orphan or otherwise (FDA database, 2015).

Assessing Risk of Orphan Drug (OD) Regulatory Approval
Drug development portfolios vary in extensiveness and depth. For each company,
the objective of improving the success rate of their marketing applications is paramount.
Regardless of the many Orphan Drug Act (ODA) incentives, pharmaceutical companies
undertake a huge risk when pursing the registration of an orphan drug. Understanding some
of the characteristics associated with marketing application success for these special drugs
and alternatively some of the pitfalls associated with application failure may assist
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pharmaceutical companies in developing more efficient regulatory strategies for orphan
drug registration.
Each pharmaceutical company conducts risk assessments using customized
algorithms or models. Each company rate or value differently all the factors associated with
the probability of regulatory success and subsequently marketing of drugs. The probability
of regulatory success also known as PRS provides a qualitative description of uncertainty
suffers from vagueness and lack of collective agreement on useful definitions. A subjective
probability represents the degree of belief in an event by an individual and the
quantification of this uncertainty allows other business metrics to be specified. A careful
consideration of technical feasibility is key to portfolio management. Probability is an
excellent language for quantifying this uncertainty. PRS assessment is a well-planned
process for probability assessment and review that can provide executives with reliable
measurements of regulatory feasibility (Maniglia, 2007).
One of the most important risk recently identified associated with orphan drug
approval is an accurate and well-constructed probability of regulatory success (PRS). This
is a unique and empirical process that helps evaluate the risk associated with orphan drug
development. It is confidential by nature and its conducted by a multidisciplinary group
within the pharmaceutical company. Each contribution is vital to assets the probability of
regulatory success of an orphan drug. Some of the key members are: commercial, clinical,
safety, regulatory, finance and forecasting leads chaired by a project manager.

Probability of Regulatory Success (PRS): Components
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Figure 6. Standard Probability of Regulatory Success (PRS) model (Florent, 2015)

The probability of regulatory success is a systematic evaluation of medical, clinical,
nonclinical and regulatory questions that needed to be answered prior to regulatory
submission. Probability is an excellent language for quantifying uncertainty. A wellplanned process for probability assessment provides executives with reliable measurement
of regulatory feasibility. Probability of Regulatory Success (PRS) is multifactorial. The
most common factors evaluated in any probability of regulatory success (PRS) model are
clinical trial cost, marketing opportunity, competition and marketing cost.
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Figure 7. Probability of Regulatory Success (PRS) example (Florent, 2015)

Above figure represents a visual example of how different PRS models look in different
organizations and even in departments within the same organization. Probability of
regulatory success (PRS) models depends on many factors such as:
•

type of pharmaceutical company (ex. pharma v. biotech)

•

portfolio type (ex. cardiovascular v. oncology)

•

internal processes and practices

•

experience and empirical knowledge of the members of the multidisciplinary team.
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Net Present Values (NPV)
Currently, the only non-empirical way to evaluate the cost of drugs entering the
FDA review process is using the Probability of Regulatory Success (PTRS) together with
the Net Present Values (NPV). It is a robust mathematical way to calculate if the drug is
worth pursuing based on current expenses and future revenues as Net Present Value (NPV)
is the difference between the present value of cash inflows and the present value of cash
outflows over a period of time. NPV is used in capital budgeting and investment planning
to analyze the profitability of a projected investment or project.
The following formula is used to calculate NPV:

Figure 8. Net Present Value Formula (Kenton, 2015)
In this equation:
Rt = net cash inflow-outflows during a single period t
i = discount rate or return that could be earned in alternative investments
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t = number of time periods
NPV = (Today’s value of the expected cash flows) – (Today’s value of invested cash)

A positive net present value indicates that the projected earnings generated by a
project or investment (in present dollars) exceeds the anticipated costs, in present dollars.
It is assumed that an investment with a positive NPV will be profitable, and an investment
with a negative NPV will result in a net loss. This concept is the basis for the Net Present
Value Rule, which dictates that only investments with positive NPV values should be
considered. Apart from the formula itself, net present value can be calculated using tables,

Decision tree leads to representation of
spreadsheets, calculators, or using NPV calculator.
expected value (eNPV) - Example
Product: X
Portfolio: Pain and Inflammation
Assessment for: New Indication
ESD: 1Q2016
EAD: 2Q2018
Phase 3
Succeeds

Regulatory

PTRS

NPV

RiskAdjusted
NPV

Succeeds

70% 32%

$ 1,000

$

320

Fails

30% 13%
55% 55%

$ (200) $
$ (180) $

(26)
(99)

eNPV =

195

45%

Fails

Check:

100%

$

16

Figure 9. NPV calculation to asses PRS of a non-orphan drug (Florent, 2015).
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Figure 9 above presents a decision tree for estimating the NPV of a drug being
considered for phase III trials. It requires three (3) probabilities: the probability of technical
success for phases I, phase II and phase III. The resolution produced by NPVs depends on
these probability estimates answering the question "How do these probabilities affect a
phase's resolution?". The resolution produced by NPVs depends even more on revenue
estimates, but these estimates can be highly erroneous.
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THERORETIAL FRAMEWORK

1. Orphan Drug Research and Development.
Competition in the research-based segment of the pharmaceutical industry and it is
centered on the discovery and development of drugs that satisfy an unmet medical need or
improve upon existing therapies (Sharma et al., 2010). Research and development (R&D)
are a complex, costly, risky, and time-consuming process (Cheung et al., 2004). Over the
past decade, several economic studies have been undertaken to better understand
pharmaceutical R&D process. These studies consider cost and time needed to develop new
drugs, the economic returns to drug research and development (R&D) and probability of
regulatory success (PRS) (Yin, 2008). They highlight the large technical and commercial
risks associated with the pharmaceutical R&D process and the tremendous variability in
the economic returns of new drug introduction.
The most evident risk in drug development is that, despite a long and costly
development process, most new drug candidates will not reach the market (Grabowski,
2003). Failure can result from toxicity, carcinogenicity, manufacturing difficulties,
inconvenient dosing characteristics, inadequate efficacy, economic and competitive factors
(Grabowski, 2003). Typically, fractions of one percent (1%) of the drugs that are
synthesized and examined in pre-clinical studies make it into human testing (Grabowski,
2003). Of these, only about twenty percent (20%) of the drugs entering clinical trials
survive the development and FDA approval process (Grabowski, 2003). The prospect of a
long and uncertain development period for a new drug is another source of risk in the drug
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development process. Recent new drug approvals have averaged nine years from the
beginning of clinical trials to final FDA approval (Fagnan, Gromatzky, Stein, Fernandez
& Lo, 2013). The discovery and pre-clinical periods can add another three to five years to
this process (Fagnan et al., 2013).
In a study published in the 2003 by the Journal of Health Economics, Grabowski
examined the representative costs for new drugs whose mean introduction date was in the
late 1990s. The average cost estimate incorporates the expenditures for drug candidates
that fail in the R&D process, since these costs must be recouped from the revenues of
successful drug candidates (Grabowski, 2003). Grabowski found that it requires over $400
million in out of pocket expenditures (in 2000 dollars) to discover and develop the average
U.S. new drug introduction. If one also takes account of capital costs utilizing a risk
adjusted cost of capital appropriate for the pharmaceutical industry, capitalized R&D costs
per new drug introduction are double the out of pocket costs (DiMasi, Hansen &
Grabowski, 2003). R&D costs were shown to have increased at an annual rate of 7.4%
above general inflation when compared to the costs for new drug introductions of the 1980s
(Grabowski, 2003). A major factor accounting for this growth in costs is the size of and
number of clinical trials, which have increased significantly in the 1990s compared to
earlier periods. Another factor includes the growing complexity of trials (i.e., more
procedures per patient), an increased focus on chronic diseases, and greater costs to recruit
and maintain patients for these trials (DiMasi, Hansen & Grabowski, 2003).
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In a paper published in 2003 by Pharmaco-economics, Grabowski examined the
distribution of returns for 1990-94 new drug introductions. A key finding was that the sales
and returns of new drugs exhibit tremendous variability. In particular, Grabowski found
that a small number of drugs provide a disproportionate share of overall revenues. The
search for these exceptional drugs, which generally involves significant therapeutic
advances over establishing therapies, is a key driver of R&D competition for
pharmaceuticals companies. In 2003, Grabowski also found that the distribution of returns
is highly skewed, only three (3) of ten (10) new drugs cover the R&D costs incurred by the
average new drug (including the costs of failed drugs and discovery costs necessary to
generate new product leads) (Grabowski, 2003). Grabowski concluded that the R&D
process in very similar to winning the lottery in the sense that most drug candidates taken
into testing fail, a small number are marketed commercially and achieves modest financial
returns, and only a few drugs succeed in generating very large returns to the pharmaceutical
company (Grabowski, 2003).
The highly skewed outcomes reflect the dynamic nature of the R&D process and
the large risks that surround the process from a scientific, regulatory and commercial
perspective: the long-time delays, the need to obtain regulatory approval from the FDA,
and the new drug introductions of competitors and the various scientific and technical risks
(Grabowski, 2003). These factors help to explain the great variability in market sales and
profitability that has been observed in every cohort since the 1970s. Large pharmaceutical
companies, with extensive pipelines of new drug candidates, exhibit great variability in the
number of approvals and sales from their R&D investment in a given period (DiMasi et
al., 2003). Grabowski performed two studies on the factors that influence the size of a

45
company’s total research and development (R&D) expenditures. The two primary factors
found to be economically significant determinants of research and development (R&D)
expenditures in these studies were a pharmaceutical company’s expected returns and its
internally generated funds (Grabowski, 2003). Grabowski found that roughly 25 percent of
each million dollar change in cash flow will be directed toward increasing R&D

1. Pharmaco-Cost Benefit Approach

(Grabowski, 2003).
29

$1.5 Billions in out of pocket expenditure (2014
dollars) to discover and develop a new drug in
US.(Hay et al., 2014)

$5 Billions in capital cost. (Grabowski, 2003).

R&D cost increase at annual rate of 74% above
general inflation. (Grabowski, 2003).

Only a small number of new drugs provide big share
revenues: Fail clinical trials (70%), Achieves modest
returns (25%), Blockbuster (5%). (Grabowski, 2003).

Figure 10. New Drug research and development (R&D) expenditure Grabowski (2003).

In 1993, a study conducted by the office of technology assessment noted that the
economics of OD development and approvals might be different than other new drugs
candidates. “These products may have a different cost structure from other New Chemical
Entities (NCE), not only because of the tax credit, but also because they may involve
smaller and shorter clinical trials than other drugs” (Grabowski, 2003). Available data
sources the number of subjects enrolled in clinical trials and subsequent market sales
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suggested that research and development (R&D) cost structure of orphan drugs are indeed
different than other NCE (Grabowski, 2003). In addition to protocol assistance from the
FDA, many orphan drugs are also eligible for other orphan drug incentives such as priority
review, accelerated approval and fast track status (Hutt & Merrill, 1991). Under priority
review, the FDA goal is to review new drug applications within six (6) months or less.
Priority review is reserved for new drugs that provide a significant improvement in safety
or effectiveness. Most orphan drugs qualify for priority review but accelerated approval
however was instituted in 1992 to speed the approval of new treatment for serious or lifethreatening disease (Villarreal, 2015). This process allows approval to be granted at the
earliest phase of development at which safety and efficacy can be reasonably established.
This is often done on the basis of a single-phase II trial involving hundreds rather than
thousands of patients (DiMasi et al., 2003).

The FDA fast track program was established under the FDA Modernization Act of
1997. It consolidated the expanded FDA’s expedited development and accelerated
approval regulations to allow fast track designation for drugs with potential to address
unmet medical needs for serious or life-threatening conditions (Sharma et al., 2010). Fast
track development programs can take advantage of accelerated approval based on surrogate
end points, rolling submissions of applications for marketing approval and priority review.
Because orphan drugs are targeted to rare disease and illness, it is less likely to enroll large
numbers of patients in clinical trials in most instances (Grabowski, 2003). The total number
of subjects for orphan drugs approvals is much smaller than the average for all drugs.
Grabowski demonstrated that seven orphan drugs marketing approval in 1999 had a mean
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of 588 patients with a range between 152 and 1281 total patients in clinical trials compare
to an average of more than 5,000 subjects for a typical new drug introduction (Grabowski,
2003).
There were 27 new orphan drugs launched from 1990 to 1994 (FDA database,
2015). The top quintile earned over $500 million in its tenth year on the market (which
corresponds to the peak year for most orphan drugs) (Grabowski, 2003). By contrast, the
median quintile had ten (10) year sales of only $29.5 million and most of the drugs in the
lower two quintiles had tenth year sales of less than $10 million (Grabowski, 2003).
Clearly, these results show a tremendous heterogeneity in the sales of orphan drugs. Most
of these drugs have very modest sales, but some are just very wealthy (Grabowski, 2003).
The sales data is also strongly supportive that R&D cost structure of orphan drugs
is very different in nature from other drugs (Grabowski, 2003). In addition to the possibility
of a 50 percent tax credit, the sales of most orphan drugs would not support the large-scale
clinical trials involving several thousand patients and which can cost hundreds of millions
for the typical new drug approval (Grabowski, 2003). Based on available information on
orphan drug sales and the number of subjects listed in the available NDA approval letters,
it is reasonable to conclude that the representative orphan drug R&D costs are significantly
lower than non-orphan drugs R&D cost (Fagnan et al., 2013).
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2. Intellectual Property Strategy for Orphan Drugs

Patents have been found to be critically important to pharmaceutical companies in
appropriating the benefits from drug innovation (Bhat, 2005). The reason for this follows
directly from the characteristics of the pharmaceutical innovation process. As discussed
above, it takes several hundred million dollars to discover, develop, and gain regulatory
approval for a new drug (Grabowski, 2003). Absent of patent protection, or some
equivalent market barrier, allows imitators to free ride on the innovator's FDA approval
and duplicate the drug for a small fraction of the originator's costs (Bhat, 2005). Market
exclusivity has been essential in the pharmaceutical industry to allow pioneers to
appropriate enough of the benefits from new drug innovation to cover their large R&D
costs and earn a risk adjusted return on their overall portfolio of R&D programs (Bhat,
2005).
Economists have demonstrated the importance of patents to pharmaceutical
innovation in several studies. Yin in 2008 found that the technology industry for example
placed greater stress on factors like time and efficiencies in the production of new products
accruing to first movers in comparison to the pharmaceutical industry (Yin, 2008). This
reflects the fact that R&D costs and investment periods are larger than average in
pharmaceuticals while imitation costs are lower than in other high-tech industries.
Intellectual property rights have emerged as an important policy issue for
pharmaceutical companies (Bhat, 2005). The average gross sales margins of the US
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pharmaceutical companies during the past few years are nearly twice those of technological
companies (Bhat, 2005). Such significant differences in gross margins are primarily
attributed to the better track records of pharmaceutical companies in protecting their
innovations (Bhat, 2005). Therefore, the protection and dissemination of innovations are
great concern to pharmaceutical companies.
Bhat in 2005 argued that very few companies are willing to make huge investments
in pharmaceutical R&D without patent protection “patents support higher economic
growth as the pharmaceutical industry provides high paying jobs which in turn lead to
higher economic growth” (Bhat, 2005). Market exclusivity provided by patents yields
higher prices and profit margins to brand-name drugs. The longer is the market exclusivity;
the higher are the profits (Bhat, 2005) since the profits are typically much higher at the end
of the market exclusivity as drugs need minimal advertising and promotion.
However, prior a drug can be marketed in the United States; it needs to be approved
by the US Food and Drug Administration (FDA) as safe and effective (21 CFR§ 393).
Patent ownership by itself does not provide right to market patented drugs in the United
States (Bhat, 2005). In other words, granting patents and drug approval are two different
process overseeing by two different institutions.
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Regulatory
Institutions and Functions
Table II. Orphan Drug Approval Process in US (Florent, 2015)
15

Filling

Government
Body/Institution

Requirements

Outcome

Patent
Application

USPTO

Patentable
Novel
Non-Obviousness
Useful

Valid Patent

Patent protection
of + 25 years

ODD Application

FDA
OOPD

Mechanism of
action

ODD

Eligible for ODA
incentives

NDA/BLA
Application

FDA
CDER/CBER

Safety
Efficacy

Regulatory
approval

Legal marketing
commercialization
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Both patent ownership and drug approval are necessary for a pharmaceutical
company to sell drugs without civil or criminal liability in the United States. If a company
gets a marketing approval for a drug whose patent is not owned by the company, it could
be subjected to liability for patent infringement (Bhat, 2005).

The importance of patent protection in pharmaceuticals is further supported by
comparing innovative performance of the pharmaceutical industries in countries with and
without strong patent protection. Strong systems of patent protection exist in all countries
with strong innovative industries in pharmaceuticals (Grabowski, 2003). This is a major
finding of an analysis that Grabowski performed of the distribution of important new global
drug introductions categorized by the nationality of the originating companies for the
period 1970 and 1985. Similarly, longitudinal studies on the growth of research and
development (R&D) expenditures and foreign direct investment in Canada and Japan
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associated with changes in their patent systems for pharmaceuticals support the
significance of intellectual property rights as incentives for innovation (Fagnan et al.,
2013).
Like many other scholars have stated, patent law is considered to be stronger for
pharmaceutical companies than for other areas of technology. It seems reasonable that
other technologies could advance relatively fast even without patent protection, but in
pharmaceuticals, removal of the patent incentive would virtually eliminate private sector
drug research (Abramowicz, 2003). Private sector research depends on the patent reward
because of the extraordinary costs associated with research into new drugs and the relative
easiness with which generic drug manufacturers can copy drugs (Abramowicz, 2003).
Abramowitcz’s embrace of patent protection for pharmaceutical companies does not imply
that the general patent framework is tuned for pharmaceuticals. Indeed, the existence of
many exclusivity provisions that are specific to drugs reveals that, because of the
importance of drug development, Congress has sought to address inefficiencies and
imperfections of the patent system in that context. Pharmaceutical companies clear out of
their pipelines drugs that they do not expect to be able to patent, even though these drugs
are generally not available on the market (Parchomovsky & Siegelman, 2002). The
requirements of patentability, particularly the requirements of novelty and no obviousness
make sense to the extent that the goal of patent law is viewed as the conception of drugs
that might turn out to be clinically beneficial after a long testing process (U.S.C §102). But
if a goal is actually to encourage drug manufacturers to undertake that testing process,
patent law will work only so long as the pharmaceutical company that consider a drug
proceeds to seek a patent and then undertake the clinical testing process. Nevertheless, if a
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third party observes in a scientific publication that a particular compound seems like a very
promising drug candidate, it is less likely that an unrelated pharmaceutical company will
research that compound, because the company will be concerned that the drug will be unpatentable even if the research turns out to be successful (Parchomovsky & Siegelman,
2002).
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3. The Orphan Business Model of Orphan Drugs.

The business model of researching a compound, guiding it through the FDA
regulatory approval process, and bringing it to market is an orphan business model. As
with other orphan business models, the problem is that second movers can take advantage
of information produced by the first mover and dissipate the profits that the first mover
could have expected to receive (Abramowicz, 2003). Being first to market and being able
to offer the brand-name drug may, as a result of trademark law, provide some first-mover
advantages, but at least in many cases these benefits will be insufficient to make the
research path appear profitable, even if it would be socially beneficial (Abramowicz, 2003).
The type of information on which the second mover is free-riding is different from the
relevant information in a typical orphan business model case, where the second mover
might wait to see whether there is consumer demand rather than regulatory approval. As
with all orphan business models, though, there is a private risk that it will not be feasible
to earn a profit providing a good or service, and first movers may not be willing to make
expensive investments that have a high chance of producing no profits if second movers
can enter the market in the unlikely case success is achieved (Parchomovsky & Siegelman,
2002).

The Orphan Drug Act seeks to protect orphan drugs in this context, drugs that need
to be adopted by a pharmaceutical company if they are to be brought to market
(Abramowicz, 2003). The title of the statute might at first appear to be a contradiction
because it applies to any drug that is for a rare disease, but the definition of rare disease or
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condition is expansive. It includes not only any disease that affects less than 200,000
persons in the United States, but also any disease that “affects more than 200,000 in the
United States and for which there is no reasonable expectation that the cost of developing
and making available in the United States a drug for such disease or condition will be
recovered from sales in the United States of such drug” (U.S.C §360). In other words, the
statute presumes that a drug for a disease affecting a relatively small number of people
needs protection because there will generally be reduced incentives to develop drugs for
smaller patient populations. The statute, however, in theory also allows pharmaceutical
companies to demonstrate that a drug affecting a larger number of people needs protection.
For any drug designated for a rare disease the statute provides seven (7) years of marketing
exclusivity (U.S.C §360). However, exclusivity can be cancelled if the pharmaceutical
company cannot assure the availability of sufficient quantities of the drug (U.S.C §360).
Outside the United States, numerous countries and the European Union have adopted
statutes similar to the Orphan Drug Act (Sharma et al., 2010).

Most studies of the Orphan Drug Act indicate that it has helped promote further
research into drugs for rare diseases. Dr. Yin finds that the Orphan Drug Act promotes drug
development, and the effect is greater for more prevalent rare diseases (Yin, 2008). There
is an argument, however, about whether the Orphan Drug Act itself provides the primary
incentives that induce the development of drugs that are brought to market (Abramowicz,
2003). Other scholars argue that the Orphan Drug Act has in some instances provided
protection that was unnecessary to induce drug development. These scholars noted that
some orphan drugs have earned more than $1 billion per year, suggesting that they could
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have been developed even without an orphan designation (Grabowski, 2003). While
incentives provided for pharmaceutical companies by the Orphan Drug Act (ODA) have
helped hundreds of treatments for rare diseases enter the market, ethicists, scientists, and
many others argue that some pharmaceutical companies have exploited the law to gain
profits.

A key provision of the ODA is that each time a medication gets approved by the
FDA to treat a rare disease, it gains an additional seven years of market exclusivity for the
specified condition, giving companies the ability to charge high fees for an extended period
of time. In 2015, a Kaiser Health News (KHN) investigation revealed that a number of
pharmaceutical companies gamed the system to sell orphan drugs at astronomical prices
by using two key strategies: repurposing commonly used drugs and getting approval to use
one product for multiple orphan diseases (KHN, 2015).
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2. Intellectual Property Strategy Approach (continue)
Table III. Intellectual Property Strategies (Florent, 2015).

32

IP Strategy

Definition

Example

OD
Development

A drug that has been developed for a
yet untreated rare disease.

Lumizyme® (alglucosidase
Alfa) for Pompeii disease.

Repurposing

A drug developed to treat a common
Viagra® (sildenafil) for
disease but now it has been repurposed Erectile Dysfunction (ED)
to treat a rare disease.
now for the treatment of
pulmonary hypertension
(PAH) Revatio® (sildenafil)

Maximizing
portfolio

A drugs developed to treat of rare
disease that now treats a common
disease.
©2015 M. Florent

Ilaris® (Canakinumab) for
Muckel-Wells Syndrome
(MWS) now for the
treatment of Rheumatoid
Arthritis (RA)

For example, AbbVie’s HumiraÒ, which was FDA-approved in 2003 to treat
rheumatoid arthritis, a condition that affects around 1 million adults in the U.S. alone, later
gained additional approvals for multiple indications with orphan designation, including
juvenile rheumatoid arthritis and pediatric Crohn’s disease giving the company market
exclusivity for some of these conditions until the early 2020s. HumiraÒ is not a true orphan
drug. In fact, HumiraÒ is currently one of the world’s best-selling medications as in 2017,
it raked in $18 billion in sales. This strategy is well known in the industry as repurposing.

Another technique is to identify additional populations to gain orphan drug
approvals in a practice known as maximizing portfolio in which a more common condition
is divided into smaller, biomarker-defined categories. A 2016 study found that 13 of the 84
drugs approved with orphan designation between 2009 and 2015 were for subsets of
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prevalent diseases and that some of those medications were also approved for other, related
conditions (FDA database, 2018). For example, pharma firm Boehringer Ingelheim
received FDA approval for GilotrifÒ (afatinib) to treat Non-Small Cell Lung Cancer
(NSCLC) patients with an EGFR mutation in 2013. Then, in 2016, the company received
approval to use the same drug to treat NSCLC patients with squamous histology. The firm
was awarded seven years of market exclusivity for both of the specified indications (FDA
database, 2018). The ODA doesn’t discriminate between genuinely rare conditions where
there’s usually a hereditary component, almost always in children, versus personalized
approaches to cancer where clearly, they still are rare, but they are a different end of the
spectrum.
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CONCEPTUAL FRAMEWORK

Extracting factors from most theories in the industry and understanding the nature

Conceptual Frame Proposal based on
Literature Review
with probability of regulatory success:

of orphan drugs below in Figure 11. is a proposed conceptual frame of factors associated
34

Clinical
trials
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R&D
cost
+

+

ODTC

+

=

Clinical trials
participation

PRS
OD
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Figure 11. Conceptual Framework for Probability of Regulatory Success of Orphan Drugs
(Florent, 2015).

The premise is that factors stated above research and developing (R&D) cost,
clinical trial duration, clinical trial participation and Orphan Drug Tax Credit (ODT) are
identified factors that are equally associated to probability of regulatory success (PRS) of
orphan drugs (OD).
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The average cost estimate incorporates the expenditures for drug candidates that
fail in the research and development process, since these costs must be recouped from the
revenues of successful drug candidates. Using the information from the literature, if
pharmaceutical companies look for drugs already approved in their portfolio and apply the
repurposing approach (Intellectual Property Theory) it would save more than $400 millions
in capital investment and another $200 millions in research and developing cost
specifically during discovery phase (in 2012 dollars) (Abramowicz, 2003). A major factor
accounting for lower costs is the smaller clinical trials and to low complexity of trials due
to fewer participants.

In 1993, a study conducted by the office of technology assessment noted that the
economics of orphan drug development and approvals might be different than other new
drugs candidates. As explained earlier, these products may have a different cost structure
from non-orphan drugs, not only because of the tax credit, but also because they may
involve smaller and shorter clinical trials. Available data from FDA sources the number of
subjects enrolled in clinical trials and subsequent market sales, suggesting that orphan
drugs are indeed different than non-orphan drugs. Because orphan drugs are targeted to
rare disease and illness, it may not be feasible to enroll large numbers of patients in clinical
trials in most instances. The total number of subjects for orphan drugs approvals is much
smaller than the average for non-orphan drugs.
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CHAPTER III
METHODOLOGY
Introduction
The Orphan Drug topic has been investigated widely since 1970s and orphan drugs
research subject have varied significantly over the last 50 decades. Most of the orphan
drugs studies available today focus primarily on qualitative research. The methodology for
evaluating factors associated with orphan drugs development and regulatory success is
often empirical. There are no standard research methods for this topic in general and
researchers are limited to observe and report data from their points of view. Consequently,
validity and reproducibility of data is an issue when investigating orphan drugs (Yin, 2016).

Among different methods of data collection commonly used in orphan drug
research are observation, interview and questionnaire. Over the last 30 years, scholars have
used observation and recorded in narrative or descriptive format to present and analyze the
data collected. The tools of research to study orphan drugs can be similar to any other topic
in healthcare: observation and description of phenomena; questionnaires seeking data from
large numbers of participants, experimental investigation of specific problems, particularly
by means of tests; genetic studies; and statistical analysis of the data collected. However,
the subject of orphan drugs is so broad and deep that consists in much more than simple
applied science; problems which have formed the leading subjects for research fall under
one of two main categories: a) orphan drug trends and b) orphan drugs developing cost.
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Factors associated with orphan drug regulatory success have not been extensively
investigated in the pharmaceutical industry and some companies may claim to have
actually quantified how factors affect the probability of regulatory success (PRS) however
this information is considered confidential and it is share only internally meaning it is not
available in the public domain. Confidential information is also considered property of the
disclosing party and for the purpose of this study the disclosing party are the
pharmaceutical companies that impose contracts to employees who are bound to honor this
agreement.

It is challenging to obtain data to analyze factors that are associated with regulatory
success of orphan drugs. Due to trade secret clauses, non-disclosure agreements and
confidentiality agreements that pharmaceutical companies impose over its employees,
some researches are limited to information available in public databases. For example,
many researchers have utilized the US FDA orphan drug product designation website to
identify the comprehensive list of drugs which have been approved by the FDA and given
orphan status in the US since the establishment of the Orphan Drug Act (ODA) in 1983.
Other scholars for example have analyzed the IMS Health MIDAS database to assess
orphan drug and total drug expenditures in the US. Some international investigators have
used analysis focused on expenditures of orphan drugs that were approved for both orphan
and non-orphan indications. In the case of healthcare professional such as physicians,
nurses, pharmacist and many others that work closely with patients and families that suffer
from any rare diseases, the most common methodology is to apply a survey to a
representative sample targeting patients and their families whose experiences can be
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generalized to the target universe, even if that universe is small which is the case of rare
diseases. However, none of the approaches mentioned above are optimal when evaluating
factors associated with regulatory success of orphan drugs therefore a meta-analysis is the
proper tool to use since it integrates the results of several independent studies. For this
particular topic, a quantitative meta-analysis provides a more precise estimate of the effects
of factors that improve the probability of regulatory success (PRS) of orphan drugs than
any individual study contributing to the pooled.

Research Design
•

Longitudinal (1999-2017).

•

Systematic literature review of published literature.

•

Quantitative meta-analysis and meta-regression.

•

Total population (N= 672) (number of articles used in study)

•

Not human subject type of research (IRB exempt)

Institutional Review Board (IRB)
The Institutional Review Board (IRB) is an administrative body established in a
teaching or researching institution (hospitals and universities) to protect the rights and
welfare of human research subjects recruited to participate in research activities conducted
under the auspices of the institution with which it is affiliated. The IRB is charged with the
responsibility of reviewing, prior to its initiation, all research involving human participants.
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Seton Hall University's Institutional Review Board for Human Subjects Research
(IRB) has been established in accordance with federal regulations. This IRB reviews all
proposed research involving human subjects in order to ensure that subjects' rights and
welfare are adequately protected.
The University's IRB Office is administered and empowered through the Office of
the Provost. The IRB is comprised primarily of faculty members from disciplines that
conduct research involving human subjects (i.e., nursing, allied health fields, education,
psychology, sociology, etc.). Community representatives who have no formal ties to the
University also sit on the IRB. The Board's membership, policies and procedures are
governed by an Assurance Agreement filed with the United States government.
Under Seton Hall University's Assurance Agreement filed with the U.S.
Department of Health and Human Services (HHS), all generalizable research activities
involving human subjects, whether federally funded, privately-funded or non-funded,
including dissertations, master's theses, pilot studies, class projects, and non-funded
faculty-directed research, must be reviewed and approved by the University's IRB prior to
conducting the research, if the proposed research meets any of the following conditions:
•

the research is sponsored by the University, or

•

the research is conducted by or under the direction of any University employee, or
agent (e.g., faculty member, researcher, or student) in connection with his/her other
institutional responsibilities, or
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•

the research is conducted by or under the direction of any University employee or
agent (e.g., faculty member, researcher, or student) using any University property
or facility, or

•

the research involves the use of the University's non-public information to identify
or contact human research subjects or prospective subjects, or

•

the research involves the use of the University's students, employees, or facilities.

On November 10th, 2017, this study was submitted to the Institutional Review Board
at Seton Hall University. In the application, it was stated that this research involved
conducting a quantitative systematic literature review of published literature (Metaanalysis) with no human subjects. On December 6th, 2017 the board requested additional
documentation specifically an updated Federal Wide Assurance (FWA) from employer
Pfizer, Inc. A Federal Wide Assurance (FWA) is the documentation of an institution's
commitment (in this case Pfizer, Inc) to comply with Federal regulations and maintain
policies and procedures for the protection of human participants since Pfizer, Inc. does not
have an internal IRB process for this type of research study. The IRB at Seton Hall
University carefully and fairly evaluated the response in reaching its final determination.
On April 16th, 2018 the Director of the Institutional Review Board (IRB) at Seton Hall
University responded with a written statement stating the IRB application cannot be review
since it does not fall under the purview of the IRB, not even in exempt status as this study
does not involved human subjects testing. A systematic literature review and meta-analysis
of data is not considered human subject research (U.S. Department of Health and Human
Services, 2018). (See Appendices A, B and C).
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Data Collection
•

Relevant data was be collected regarding the clinical development and approval
of orphan drugs that first entered clinical testing anywhere in the world from
1999 to 2017 as published in peer review literature common to the
pharmaceutical industry.

•

The data elements selected from this larger dataset was generic name, trade
name, dates of when clinical testing phases commenced, the development status
of the compound, and the indications pursued prior to original marketing or
termination of development on the investigational compound. All information
can be sourced from the previously mentioned published peer review literature.

•

Factors will be grouped into four factor categories: 1) characteristics of the
molecule itself, 2) economic factors that relate to potential markets for the drugs
and the size of the company developing the drug, 3) features of trial design, and
4) the safety and efficacy outcomes of the clinical trials.

Methodology
1. Systematic Review
On May 21st, 2015 a pilot was conducted in order to understand the length of the
work ahead and make a realistic determination of how much time and resources it would
be needed to complete this study conducting a full meta-analysis. The literature search was
undertaken between May 1st 2015 and March 30th, 2017 to identify published peerreviewed articles in English. The databases searched use were MedlineÔ, PubMedÔ
GoogleÔ Scholar, Springer LinksÔ, ScopuÔ, Cochrane Library AcademicÔ. A search was
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also conducted in the following journals: Health Policy, Pharma-economics, Orphan
Drugs: Research and the Orphanet Journal of Rare Diseases.

A search strategy was developed and implemented under the leadership of the
committee. Multiple keywords including but not limiting to the following were used:
(“Orphan drugs” or “Orphan drugs clinical trials” or “Clinical trials”) and (“Orphan” or
“clinical trial length”) and (“Orphan Medicines” or “Orphan Drugs” or “Orphan
Pharmaceuticals”) and (“Drugs” or “Medicines” or “Pharmaceuticals”) and (“Regulation”
or “Policy” or “legislation”) (“Pharmaco-economic” or “orphan drug business model” or
“orphan research and development”) and (“Orphan” or “clinical trial length”) and (“Orphan
Drug Approval ” or “Orphan Drugs designation”) and (“Drugs assessment” or “PRS” or
“Probability of regulatory success”) and (“Orphan Drug developing cost” or “R&D
developing risk” “R&D cost”) and (“” or “” or “”) and (“” or “”). The keywords were
combined and integrated in database and journal searches. Search results (‘hits’) by
database and journal were tabulated and printed. The terms used were searched using
‘AND’ to combine the keywords listed and using ‘OR’ to remove search duplication where
possible. References of retrieved articles were assessed for relevant articles that our
searches may have missed.

Meta-Analysis: Data Abstraction
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Included

Eligibility

Screening

Identification

49

Publications identified
through database searching
(n=500)

Potentially relevant articles
retrieved for detailed
examination (n= 216)
Full text articles/abstract
assessed for eligibility
(n=108)

Duplicates
Relevance
Lack of abstract/additional
information
English
(n=284)
Applied
inclusion/exclusion
criteria
(n=108)
Further research
(n=24) were identified
©2018 M. Florent

Final inclusion for the metaanalysis (n=132)

Assumption of adequate power based on
my methodology is substantiated on
Valentini et al, 2010.

Figure 12. Data Abstraction: PRISMA Flow Chart in Meta-analysis (Florent, 2018)

From the database/journal searches 500 titles/abstracts were retrieved. The title and
abstract of all retrieved articles were reviewed for relevance. Subsets of research results
were checked by the committee chair. If there was any ambiguity with regards to the paper,
the full-text article was retrieved and reviewed for relevance. After removing duplicates
and titles/abstracts unrelated to orphan drugs or rare diseases, a total of 216 peer-reviewed
English- language articles were identified. Original articles, reviews, commentaries and
opinions of they described “key words” for orphan drugs and relevant health services were
included. Of these, only 108 articles were relevant to research topic; thus, with guidance
from the committee articles in full were read. Six more articles were identified from
references of the retrieved articles; thus 24 articles were considered against the study
inclusion and exclusion criteria (see Appendix D).
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The literature was systematically reviewed to ensure that a narrative synthesis
produced was sourced from the most complete collection of relevant literature possible.
Thematic analysis of the articles was conducted, and relevant sub-categories were created
for examination until no more themes were identified and saturation was deemed to be
reached. Using these categories generated by the analysis, the range and types of factors
associated with the probability of regulatory success of orphan drugs were described. Once
sample of studies (n=132) were collected The Comprehensive Meta-Analysis (CMA) v.3.0
software coded their characteristics and calculated effects sizes.

2. Meta-analysis
Glass first defined meta-analysis in the social science literature as "the statistical
analysis of a large collection of analysis results from individual studies for the purpose of
integrating the findings" (Glass, 1976). Meta-analysis is a quantitative, formal,
epidemiological study design used to systematically assess the results of previous research
to derive conclusions about that body of research. Typically, but not necessarily, the study
is based on randomized, controlled clinical trials. Outcomes from a meta-analysis may
include a more precise estimate of the effect of treatment or factor for disease, or other
outcomes, than any individual study contributing to the pooled analysis (Glass, 1976).
Identifying sources of variation in responses; that is, examining heterogeneity of a group
of studies, and generalizability of responses can lead to more effective treatments or
modifications of management. Examination of heterogeneity is perhaps the most important
task in meta-analysis (Oxman & Guyatt, 1993).
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Figure 13. Meta-Analysis in Quantitative Research (Glass, 1976).

Meta-analyses are conducted to assess the strength of evidence present on a disease
and treatment. In this particular study one aim to determine whether an effect of factors
associated to regulatory success exists and whether the effect is positive or negative. The
results of a meta-analysis can improve precision of estimates of effect, answering questions
not posed by the individual studies, settle controversies arising from apparently conflicting
studies, and generate new hypotheses. In particular, the examination of heterogeneity is
vital to the development of new hypotheses (Oxman & Guyatt, 1993).
A sound meta-analysis is characterized by a thorough and disciplined literature
search. A clear definition of hypotheses to be investigated provides the framework for such
investigation (Oxman & Guyatt, 1993). Studies are chosen for meta-analysis based on
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inclusion-exclusion criteria. Inclusion criteria are ideally defined at the stage of initial
development of the study protocol. The rationale for the criteria for study selection used
should be clearly stated. When studies are excluded from a meta-analysis, reasons for
exclusion should be provided for each excluded study (Oxman & Guyatt, 1993). Usually,
more than one “assessor” decides independently which studies to include or exclude,
together with a well-defined checklist and a procedure that is followed when the assessors
disagree (Haidich, 2010). Two people familiar with the study topic perform the quality
assessment for each study, independently and this is followed by a consensus meeting to
discuss the studies excluded or included (Haidich, 2010).

Although the intent of a meta-analysis is to find and assess all studies meeting the
inclusion criteria, it is not always possible to obtain these. There is good reason to be
concerned about this potential loss because studies with significant, positive results
(positive studies) are more likely to be published and, in the case of interventions with a
commercial value, to be promoted, than studies with non-significant or "negative" results
(negative studies) (Oxman & Guyatt, 1993). Studies that produce a positive result,
especially large studies, are more likely to have been published and, conversely, there has
been a reluctance to publish small studies that have non-significant results (Haidich, 2010).
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Summary
•

Meta-analysis is a statistical technique for combining the findings from independent
studies.

•

The validity of the meta-analysis depends on the quality of the systematic review on
which it is based.

•

A good meta-analysis aims for complete coverage of all relevant studies, look for the
presence of heterogeneity, and explore the robustness of the main findings using
sensitivity analysis.

Meta-Analysis: Steps
46

1. Data Sourcing
2. Data Selection
3. Data Abstraction
4. Data Analysis
Figure 14. Steps in Meta-Analysis (PRISMA,
guidelines,
2018). 2018.
Source: PRISMA
guidelines,
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There are four steps involved in meta-analysis but first the problem needs to be
addressed and specified in the form of clear, unambiguous and structured question before
beginning the review work. Once the review questions have been set, modifications to the
protocol should be allowed only if alternative ways of defining the populations,
interventions, outcomes or study designs become apparent.

Data Sourcing: the search for studies should be extensive. Multiple resources (both
computerized and printed) should be searched without language restrictions. The study
selection criteria should flow directly from the review questions and be specified a priori.
Reasons for inclusion and exclusion should be recorded.

Data Selection: Study quality assessment is relevant to every step of a review.
Question formulation and study selection criteria should describe the minimum acceptable
level of design. Selected studies should be subjected to a more refined quality assessment
by use of general critical appraisal guides and design-based quality checklists. These
detailed quality assessments will be used for exploring heterogeneity and informing
decisions regarding suitability of meta-analysis. In addition, they help in assessing the
strength of inferences and making recommendations for future research.

Data Abstraction: data synthesis consists of tabulation of study characteristics,
quality and effects as well as use of statistical methods for exploring differences between
studies and combining their effects (meta-analysis). Exploration of heterogeneity and its
sources should be planned in advance. If an overall meta-analysis cannot be done, subgroup
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meta-analysis may be feasible.

Data Analysis: the issues highlighted in each of the four steps above should be met.
The risk of publication bias and related biases should be explored. Exploration for
heterogeneity should help determine whether the overall summary can be trusted, and, if
not, the effects observed in high-quality studies should be used for generating inferences.
Any recommendations should be graded by reference to the strengths and weaknesses of
the evidence.

2.1 Inclusion and Exclusion Criteria
A meta-analysis carried out on a rigorous systematic review can overcome dangers offering
an unbiased synthesis of the empirical data (Oxman et al., 1995). Table 1 below describe
main criteria use to select o rejects studies in this meta-analysis.
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Table IV. Data Selection: Meta-Analysis Inclusion/Exclusion Criteria. (Florent, 2018)
Inclusion Criteria

Exclusion Criteria

Recent publications 2005 onwards

Older publications

Publications with keys words: number

Publications that discuss product specific or

of patients enrolled in clinical trials,

disease specific.

length of clinical trial, patent strategy,

Publication out of the scope/relevance to

market exclusivity for OD, size of

this study

company, OD legislation, ODD and OD
approval
Experimental publications, reviews and

EU, EM study that does not discuss/mention

expert opinions that only discusses

OD Approval

ODD
Publications from emerging markets if

Price and reimbursement, impact on patients

discuss or analysis ODD and factors

and families, funding.

associated with designation in the

Articles with unfamiliar/standardized

market.

methods
Publications that lack information about
data collection.
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2.2 Validity and Reliability
In order to determine if a meta-analysis is valid and reliable, a series of protocols
were followed, and tests were conducted:
1. An appropriate systematic review.
2. Cochrane guidance were followed on developing and refining search
terms.
3. Clear inclusion/exclusion criteria. A list of validity threats was used as
bases for exclusion (Cook & Campbell, 1979) and consider whether
each might have influenced studies in my analysis.

A meta-analysis that combines the results from many trials, have more
power to detect small but clinically significant effects. Furthermore, they give more
precise estimates of the size of any effects uncovered (Oxman et al., 1995). In order
to determine if a meta-analysis is valid and reliable, a series of questions need to be
asked. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses
better known as PRISMA was used. PRISMA is an evidence-based minimum set
of items for reporting in systematic reviews and meta-analyses. PRISMA focuses
on the reporting of reviews evaluating randomized trials but can also be used as a
basis for reporting systematic reviews of other types of research, particularly
evaluations of interventions. In addition, the Cochrane Collaboration PRISMA
flowchart was utilized to demonstrate screening.
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3) Statistical Analysis
A variety of statistical analysis was used to assess a large set of publicly available
factors as the basis for creating and testing a straightforward, simple algorithm that would
better predict probability of regulatory success of orphan drugs. Such an algorithm would
provide a more precise estimate than one can be obtained by utilizing only success rate
estimates based on historical industry data for drugs in general, or by therapeutic class.
a) Statistical analysis and inference (associations and logistic regressions):
data was be examined by applying a number of statistical inference
techniques.
•

Identify factors associated with probability of regulatory success
of orphan drugs (meta-analysis)

•

Linear regression (meta-regression) to evaluate factors
associated with probability of regulatory success of orphan drug

•

Compare factors previous identity to be associated with
probability of regulatory success of orphan drugs (Meta-analysis
subgroups). Association statistics between each potential factor
and a categorical variable for regulatory approval success or
failure.

•

Nonparametric X2 tests (assumption of normality) of association
will then applied to determine which factors have statistically
significant association with probability of regulatory success of
orphan drugs.
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b) “AODI” (Approved Orphan Drug Index) algorithm: based on the
variety of mathematical and statistical techniques, predictors for a
scoring algorithm to three factors will be used. Those factors are: 1) the
number of subjects enrolled a clinical trial phase II trial, 2) the length of
the clinical trial phase II period and 3) the number of patients affected
by the rare disease (prevalence).

Software
Comprehensive Meta-Analysis (CMA) v.3.0 Software
Comprehensive Meta-analysis is an essential tool for efficient problem solving in
meta-analysis. Comprehensive Meta-Analysis (CMA) software is user friendly with a
simple and clear interface (like an excel sheet) that guides to do complicated meta-analysis.
The formats included in the software allow researchers to input data in various ways. It
provides clear outputs and high-resolution graphs that can be imported to Microsoft
WordÒ. There is a feature that shows calculation steps and provides advance sub-group
analysis, moderator analysis, meta-regression and publication-bias analysis.

78

Figure 15. Effect Sizes and Study Weights in Comprehensive Meta-Analysis software
(CMA, 2018)

The program was developed partly as an educational tool, and it includes many
features that help explain the process of meta-analysis. CMA can be used to create a forest
plot which shows each of the individual studies and the combined effect size. CMA also
allows manipulation of the studies to see how these modifications impact the weight
assigned to each study and how they impact the summary effect. CMA can also see how
the selection of a model (fixed-effect vs. random-effects) impacts the analysis.
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IBMÔ SPSS® Statistics Software v.23
IBMÔ SPSS® Statistics is an essential tool of assessment and it is widely used for
statistical analysis in social science. SPSS® is also used by marketing, health, government
and education researchers. The original SPSS manual has been described as one of
sociology's most influential books for allowing ordinary researchers to do their own
statistical analysis (Nie, Bent & Hull, 1970). In addition to statistical analysis, IBMÔ
SPSS® Statistics is ideal for data management (case selection, file reshaping, etc.) and data
documentation (data master file).

IBMÔ SPSS® Regression Software v.23
IBM SPSS® Regression software predicts categorical outcomes and applies a range
of nonlinear regression procedures. This software allows uses regression techniques where
research is limited such as a meta-analysis. SPSS Regression software allows expanding
the capabilities of IBMÔ SPSSÒ Statistics Base for the data analysis stage in the analytical
process.
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Figure 16. IBMÔ SPSSÒ regression software v.23 (Florent, 2018)
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CHAPTER IV
RESULTS

PART 1: Exploratory Research
In the first part, the objective of this study is to identify, compare and evaluate factors
associated with probability of regulatory success of orphan drugs (OD).

1. Summary of Findings from Systematic Review
A systematic review provides a summary of the data from the results of a number
of individual studies. If the results of the individual studies are similar, frequency
percentages are used to combine the results from the individual studies and an overall
summary estimate. A systematic review gives weighted values to each of the individual
studies according to their size.

Table V. Predominant areas of research in Orphan Drugs Literature (Florent, 2018).
Area of Research

Frequency %

ODBM

27

20.45

R&D

47

35.60

OD Policy

31

23.48

Clinical Trials

10

7.57

Pharmaco-economics

5

3.78

Intellectual Property

12

9.09

TOTAL

132

100
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While the term systematic review typically invokes the process of combining
findings across studies to determine the effect, in this study the term describes the selection
of studies with a common trait. Table above shows the results of a systematic review also
after examining 132 studies. Orphan Drug Business Model (ODBM), Research and
Development (R&D) and orphan drug policy were the highest research areas found.

Table VI. Sub-categories within Research and Development (R&D) (Florent, 2018)
Area of Research Sub-categories (factors)

%

Research and

Research and development (R&D)

7

development

Orphan drug (OD) development cost

35

(R&D)

Competition

55

Orphan drug tax credit (ODT)

3

When looking at sub-category Research and Development (R&D); competition
and Orphan Drug (OD) development scored very high with 55% and 35% respectively.

Table VII. Sub-category within Orphan Drug Policy (Florent, 2018).
Area of Research

Sub-categories

%

Orphan Drug (OD)

Prevalence

59

Policy

Market Exclusivity

25

Policy framework review

16
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When looking at sub-category OD policy: prevalence and market exclusivity
scored very high with 59% and 25% respectively.

Table VIII. Sub-category Orphan Drug Business Model (ODBM) (Florent, 2018).
Area of Research

Sub-categories

%

Orphan drug business model

Company size

19

(ODBM)

Clinical trial duration

43

Clinical trial participation

27

Regulatory approval

11

timelines

When looking at sub-category Orphan Drugs Business Model (ODBM); clinical
trial duration scored 43% and clinical trial participation scored 27% leaving company
size 19% and regulatory approval timelines 11% in 3rd and 4th place respectively.

2. Summary of Findings from Quantitative Meta-Analysis
Meta-analysis is defined as a quantitative synthesis of information from several
studies. However, a qualitative meta-analysis, not to be mistaken for a systematic
review, can allow for the systematic review of qualitative studies in a way that is more
interpretive than aggregative.
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Table IX. Factors Associated with Probability of Regulatory Success of Orphan Drug
(Florent, 2018).
Factors associated with Orphan Drug

%

p. value

Clinical trial duration

36.7

0.0015

Rare disease prevalence

21.1

0.0020

Research and development cost

3.95

0.01

Number of participants in clinical trials

16.1

0.0068

Company size

2

0.0401

Regulatory Success

p. <0.005 value for statistical significance

This table shows results of factors associated with probability of regulatory success
of orphan drugs. The analysis showed that three of out five factors were identified to have
statistical association with probability of regulatory success of orphan drugs. Clinical trials
duration showed 36.7% of association with probability of regulatory success of orphan
drugs with a p. value of 0.0015 meaning there is statistical significance in these results.
Rare disease prevalence showed 21.1% of association with probability of regulatory
success of orphan drugs with a p. value of 0.0020 meaning there is statistical significance
in these results. Finally, clinical trial participation showed only 3.95% of association with
probability of regulatory success of orphan drugs with a p. value of 0.0068 meaning there
is statistical significance in these results.
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3. Summary of Findings from Meta-Regression
The following results were obtained after conducting a meta-regression with the
objective of comparing relevant factors associated with probability of regulatory success
of orphan drugs that showed significant results in the quantitative meta-analysis.

Table X. Univariate Association (together) between Potential Predictive Factors and the
Probability of Regulatory Success (PRS) of Orphan Drugs (OD) (Florent, 2018)
Variable

Coefficient SE

p. value

Odds
Ratio

Intercept

-1.0382

0.6616

0.1166

Number of patients enrolled in Clinical Trials

-0.6413

0.5386

0.2338

13.606

Prevalence of Rare disease

-0.8858

0.5159

0.0860

0.170

Duration of Clinical Trials

-0.07349

0.5431

0.1760

3.230

Coefficient negative values represent possible inverse association
Odds ratio highlighted represent possible high association
p. <0.005 value for statistical significance

Table X. shows results of a logistic meta-regression. The test is an univariate
association (evaluating together) between selected potential predictive factors and
probability of regulatory success of orphan drugs. The regression analysis showed an
inverse association between probability of regulatory success of orphan drugs and the
independent variables. The intercept is -1.0382 with a p. value of 0.1166 meaning there is
no statistical significance in these results. Also, the results from the logistic regression
show an odds ratio of 13.606 for clinical trial participation. After conducting the statistical
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inference of logistic regressions linking three of the factors: clinical trial participation,
clinical trial duration and rare disease prevalence; none of them provided a useful basis for
predictive purposes as they didn’t show significant statistical results to hold up as useful
predictors however the results from this meta-regression provide information regarding the
weights and directionality of each factors as they associate with probability of regulatory
success of orphan drugs .

After identifying and comparing factors associated with probability of regulatory
success of orphan drugs, the next step is to evaluate the factors associated with the
probability of regulatory success of orphan drugs in an isolation univariate association.
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Table XI. Univariate Association (in isolation) between potential predictive factors and
the Probability of Regulatory Success (PRS) of Orphan Drugs (OD) (Florent, 2018).
Factor

Factor value

Percentage

p. value

Approved (%)
Clinical trial duration

Rare disease prevalence

Orphan drug development cost

Clinical trial participation

<18 months

46.7

18-36 months

14.8

>36 months

8

<50,000

39.1

50,000-200,000

23.8

> 200,000

8.3

<25,000MM

16.3

>25,000MM

36.7

<500 subjects

45.7

> 500 subjects

16.1

0.0015

0.0020

0.0401

0.0010

p. <0.005 (value for statistical significance)

Table XI. above shows the results of the univariate associations between selected
potential predictive factors and probability of regulatory success of orphan drug and nonorphan drugs. Univariate Associations (nonparametric chi-square test of association) was
conducted considering individual factors in isolation. Only three variables had statistically
significant associations with probability of regulatory success. No all variables needed to
hold up as useful predictors in a multivariate context. Table XI. above lists these variables
and the cutoffs used for groupings of the four continuous variables. Three of the variables
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have high significant association with probability of regulatory success of orphan drugs.
These results suggest that clinical trials duration, clinical trial participation and the rare
disease prevalence are inversely associated with probability of regulatory success of orphan
drugs. Other factors analyzed but not show in this table were: pharmaceutical form (oral
compound. v injections) p. 0.263 and company size (small v. large) p. 0.173
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Summary PART I: Exploratory Research
Table XII. Summary of Part I: Exploratory Research (Florent, 2018)
Research Question

Hypothesis

Outcome

Is it possible to identify the

H1: Yes, it is possible to identify

Fail to reject the hypothesis H1

relevant factors associated with

the relevant factors associated

regulatory approval of orphan

with

drugs (OD)?

Orphan Drugs (OD)

regulatory

approval

of

H1ο: No, it is not possible to
identify
associated

the

relevant
with

factors

regulatory

approval of Orphan Drugs (OD)
RQ2: Is it possible to compare

H2: Yes, it is possible to

Fail to reject the null hypothesis

the relevant factors associated

compare the relevant factors

H2ο

with regulatory approval of

associated with regulatory

orphan drugs (OD)?

approval for Orphan Drugs (OD)
H2ο: No, it is not possible to
compare the relevant factors
associated with regulatory
approval of Orphan Drugs (OD)

RQ3: Is it possible to evaluate

H3: Yes, it is possible to

the relevant factors associated

evaluate the relevant factors

with regulatory approval of

associated with regulatory

Orphan Drugs (OD)?

approval of Orphan Drugs (OD)
H3ο: No, it is not possible to
evaluate the relevant factors
associated with regulatory
approval of orphan Drugs (OD)

Fail to reject the hypothesis H3
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PART II: Building an Algorithm of Approved Orphan Drug Index (AODI)
In this second part of the study, the objective is to develop and test an algorithm for
predicting probability of regulatory success of orphan drugs with the objective of providing
a tool to improve orphan drugs portfolio decision-making.

1. Construction of approved orphan drug index (AODI)
Given the results obtained from the univariate associations (factors evaluated in
isolation) between selected potential predictive factors and probability of regulatory
success of orphan drugs using a nonparametric chi-square test of association. An AODI
index was formulated as the sum of the scores for three predictive factors: clinical trials
duration, clinical participation and rare disease prevalence.

AODI (Approved Orphan Drug Index)
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Table XIII. Approved Orphan Drugs Index (AODI) (Florent, 2018).
SCORES
FACTORS

0

1

2

Clinical Trial
participation

> 500
subjects

500-250
subjects

< 250
subjects

Clinical Trial
duration

> 36
months

36-18
months

< 36
months

Rare Disease
prevalence

>500,000
patients

200,000-500,000
patients

< 200,000
patients

©2018 M. Florent
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The cut off points were assigned by the literature review and over 10 years of
regulatory experience. Higher scores of AODI are meant to be associated with higher
probabilities of regulatory success of orphan drugs.

The data suggest that there is an inverse association between clinical trial duration,
clinical trial participation and rare disease prevalence, meaning regulatory success of
orphan drugs is associated with short clinical trial duration, low clinical trial participation
and low rare disease prevalence. AODI was constructed based on results from metaregression and data available in the public domain for 100 of the drugs approved by the
FDA. For AODI to be a valuable tool and to be use in portfolio decision-making, the higher
values of the index must have greater predictive power.

2. Validation and Standardization of Approved Orphan Drug Index (AODI)

Figure 17. AODI Validation & Standardization (Florent, 2018)
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As explained before, the Approved Orphan Drug Index (AODI) can be used as a
diagnostic tool, where the condition diagnosed is probability of regulatory success of
orphan drugs. A false positive in this scenario would be an AODI score indicating eventual
marketing approval for a compound that will ultimately fail. A false negative would be an
AODI score indicating failure for a drug that would ultimately succeed.

Figure above demonstrates the extent to which higher scores for individual factors
are associated with probability of regulatory success of orphan drug. For AODI to be valid,
it had to be tested using the FDA database of clinical trial from 1999-2017 with a total of
(n=100) trials in phase II. For AODI to be a valuable tool in portfolio decision-making,
higher values of the index must have greater predictive power. Clinical trial participation
and clinical trial duration were both dominant factors. Prevalence scored low in association
with probability of regulatory success of orphan drugs. Clinical trial participation is
associated with probability of regulatory success of orphan drugs, as 61% of the drugs
tested had a score of 2. Clinical trial duration was associated with probability of regulatory
success of orphan drugs as 58% of the drugs tested had a score of 2. Rare disease prevalence
also showed to be an associated with probability of regulatory success of orphan drugs as
45% of the drugs tested scored 2. AODI proves valid and can be used as a diagnostic tool.
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Summary PART II: Building an algorithm of (AODI)
Table XIV. Summary of Part II: Building an Algorithm (Florent, 2018)
Research question

Hypothesis

Outcome

RQ4.1: Do shorter clinical trials

H4.1: Shorter clinical trials

Fail to reject the hypothesis H4.1

increase the probability of

increase the probability of

regulatory success (PRS) of

regulatory success (PRS) of

orphan drugs (OD)?

orphan drugs (OD)
H4.1ο: Shorter clinical trials
decrease the probability of
regulatory success (PRS) of
orphan drugs (OD)

RQ4.2: Do smaller clinical trials

H4.2: Smaller clinical trials

increase the probability of

increase the probability of

regulatory success of orphan

regulatory success (PRS) of

drugs (OD)?

orphan drugs (OD)

Fail to reject the hypothesis H4.2

H4.2ο: Smaller clinical trials
decrease the probability of
regulatory success (PRS) of
orphan drugs (OD)
RQ4.4: Does a lower rare

H4.4: Lower prevalence

disease prevalence increase the

increase the probability of

probability of regulatory success

regulatory success (PRS) of

of orphan drugs (OD)?

orphan drugs (OD)
H4.4ο: Lower prevalence
decrease the probability of
regulatory success (PRS) of
orphan drugs (OD)

Fail to reject the hypothesis H4.2

94
CHAPTER V
DISCUSSION
PART 1: Exploratory Research
When identifying factors associated with probability of regulatory success of
orphan drugs in the systematic review; Orphan Drug Business Model (ODBM) 20.45%,
Research and Development cost (35.60%) and Orphan Drug policy (23.48%) were the most
common theories used and applied in orphan drug regulatory risk assessment. These results
are consistent with literature review. Before the orphan drug act came into effect, academic
research began to show rising of drug development costs (Hutt & Merrill, 1991). In the
1970s, the total cost of bringing a new drug to market was $182 million (in 2012 dollars),
and by the 1980s, that number had risen to $205 million (in 2012 dollars) (Meekings,
Williams & Arrowsmith, 2012). Current estimates of the total cost to bring a new drug to
market are $1.5 billion (in 2012 dollars) (Meekings, 2012). The total cost of bringing a new
drug to market includes: out-of-pocket costs, the cost of failures and the cost of capital
(Sharma, et al., 2010) and only after a drug receives market approval, the pharmaceutical
company can begin to recover the financial (Sharma, et al., 2010). For orphan drugs, the
opportunity is diminished due to the limited pool of potential patients, which is one reason
many pharmaceutical companies find it difficult to justify the investment required to
develop treatments for rare diseases (Sharma, et al., 2010).
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When looking at sub-category research and development of orphan drugs (R&D),
competition (55%) and orphan drug development cost (35%) scored very high. This is also
consistent with the literature as there is an association between orphan drug development
and orphan drug regulatory approval. Orphan drug development is a risky venture. The
small number of patients, despite the premium price, may not lead to high revenues and
there is a significant risk of failure to reach and once this has been achieved, the probability
of getting to market is likely to be much the same as the development of a non-orphan drug.
Finch et al., 2015 addressed why both pharmaceutical and biotech companies want to
develop drugs for rare diseases and whether orphan drug development is commercially
viable mainly for the lack of competition.

When looking at sub-category orphan drug policy; rare disease prevalence (59%)
and market exclusivity (25%) scored very high. These results are supported not only by the
literature review that states that rare diseases are life-threatening or chronically debilitating
disease that affects less than 200,000 people in the US but also by previous research of
scholars in the field. It requires $1.5 Billion (in 2012 dollars) to research, develop and put
through regulatory path a new orphan drug. Given the low prevalence of rare diseases there
is a very low probability that two pharmaceutical companies would venture in a similar
treatment for the same rare disease.

When looking at sub-category Orphan Drug Business Model (ODBM); clinical trial
duration (43%) and clinical trial participation (27%) scored very high leaving company
size (19%) and regulatory approval timeliness (11%) in 3rd and 4th place respectively. Small
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patient population does not allow multiple parallel studies, so clinical study designs for
orphan drugs have to be right first time. Pharmaceutical companies received protocol
assistance for clinical trials as part of the Orphan Drug Act (ODA) incentive enrolling
patients via patient advocacy groups such as: Global Genes, National Organization for Rare
Disorders (NORD), OrphaNet and RareConnect. Clinical trial enrollment process is clearly
different for orphan drugs than for non-orphan. In addition, these results also align with
data found in FDA clinical trial database. Clinical trials for orphan drugs show small
number of participants as demonstrated by Graboski in 1999. For example, when
comparing number of participants enrolled in clinical trials for a new cardiovascular agent
versus an orphan drug approved for hemo indication, the actual numbers are 230,000 versus
5 patients. The results of this study are supported by data found in public domain (Graboski,
1999). Explaining these results when we look in the orphan drug business model approach
it seems like investing in research and development of orphan drugs for the treatment of
rare diseases is an orphan business as of nobody wants to do it. The results obtain here
explain a tangible problem pharma executive face every day when making portfolio go/no
go decisions.
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When comparing all three variables together in a multivariate context, clinical trial
duration, clinical trial participation and rare disease prevalence, the results do not hold up
meaning the result of this test was not statistically significant. See table XIV below:

Table XV. Univariate Association (together) between Potential Predictive Factors and the
Probability of Regulatory Success (PRS) of Orphan Drugs (OD) (Florent, 2018)
Variable

Coefficient

SE

p. value

Odds
Ratio

Intercept

-1.0382

0.6616

0.1166

Number of patients enrolled in Clinical Trials

-0.6413

0.5386

0.2338

13.606

Prevalence of Rare disease

-0.8858

0.5159

0.0860

0.170

Duration of Clinical Trials

-0.07349

0.5431

0.1760

3.230

Coefficient negative values represent possible inverse association
Odds ratio highlighted represent possible high association
p. <0.005 value for statistical significance

Statistical inference (logistic regressions) linked 3 variables to the probability of
regulatory success of orphan drugs. In this logistic regression, three of factors taken
together were clinical trial duration, clinical trial participation and rare disease prevalence
because they have previously been identified in the quantitative meta-analysis and have
shown significant statistical results in association with probability of regulatory approval
of orphan drugs. However, a meta-regression provides a more useful and significant
foundation for predictive purposes. The meta-regression analysis showed an inverse
association between probability of regulatory approval and the independent variables with
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an intercept value of -1.0382 and a p. value of 0.1166 meaning no statistical significance
in these results.

Nevertheless, this test proves to be extremely helpful as it guided in terms of
directionality of the three variables mentioned above. There seems to be an inverse
association between the probability of regulatory success of orphan drugs and clinical trial
duration, clinical participation and rare disease prevalence. Results about odds ratio also
provided additional information about which factor, again when evaluated together, had
higher association with probability of regulatory success of orphan drugs. Clinical trial
participation scored high at 13.606 and as explain earlier, these results are consistent with
information found in the literature review “low prevalence disease means less patients
available to enroll in clinical trial” (Grabowski, 1999).

When evaluating the same factors now in isolation using a univariate association
all three factors clinical trial duration, clinical trial participation and rare disease prevalence
showed statistical significance results in association with probability of regulatory success
of orphan drugs. An additional factor, research and development cost was included in the
test as it showed predominance in meta-analysis but no statistical significance in the
univariate association.
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Table XVI. Univariate Association (in isolation) between potential predictive factors and
Probability of Regulatory Success (PRS) of Orphan Drugs (OD) (Florent, 2018).
Factor

Factor value

Percentage

p. value

Approved (%)
Clinical trial duration

Rare disease prevalence

Orphan drug development cost

Clinical trial participation

<18 months

46.7

18-36 months

14.8

>36 months

8

<50,000

39.1

50,000-200,000

23.8

> 200,000

8.3

<25,000MM

16.3

>25,000MM

36.7

<500 subjects

45.7

> 500 subjects

16.1

0.0015

0.0020

0.0401

0.0010

p. <0.005 (value for statistical significance)

These results suggest that clinical trial duration, clinical trial participation and rare
disease prevalence (number of patients with a rare condition) are highly associated with
probability of regulatory success of orphan drugs. In addition to have statistically
significant results in the univariate association test, it also corroborates the directionality
(inverse association) of the independent variables as they associated with probability of
regulatory approval of orphan drugs. Low clinical trial participation, low prevalence and
short clinical trials are associated with higher probability of regulatory success of orphan
drugs. These results are consistent with the literature review. For example, in 1999
Grabowski demonstrated that seven orphan drugs in phase III clinical trials had a mean of
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588 patients with a range between 152 and 1281 total patients compared to an average of
more than 5,000 subjects for a non-orphan drug (Grabowski, 1999).
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PART 2: Building an Algorithm of Approved Orphan Drug Index (AODI)
In this second part of the discussion focus on the development and test process of
an algorithm for predicting probability of regulatory approval of orphan drugs in order to
provide a tool to improve orphan drugs portfolio decision-making.

First, an algorithm of Approved Orphan Drug Index also known as AODI was
constructed. Given the results obtained from the univariate associations (factors evaluated
in isolation) between clinical trial duration, clinical trial participation and prevalence of
rare disease and probability of regulatory approval of orphan drug using a nonparametric
chi-square test of association. AODI index was formulated as the sum of the scores for the
three predictive factors as they showed in previous test to be statistically significant and
also identified in the literature review.

AODI (Approved Orphan Drug Index)
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Table XVII. Approved Orphan Drugs Index (AODI) (Florent, 2018).
SCORES
FACTORS

0

1

2

Clinical Trial
participation

> 500
subjects

500-250
subjects

< 250
subjects

Clinical Trial
duration

> 36
months

36-18
months

< 36
months

Rare Disease
prevalence

>500,000
patients

200,000-500,000
patients

< 200,000
patients

©2018 M. Florent
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The results for previous test suggest that there is an inverse association between
clinical trial duration, clinical trial participation and rare disease prevalence, meaning
probability of regulatory success of orphan drugs is associated with short clinical trial
(duration), low clinical trial participation and low rare disease prevalence. AODI was
constructed based on results from meta-regression and data available in the public domain
for 100 drugs registered and approved by the FDA since 1999. For AODI to be a valuable
tool and to be use in portfolio decision-making, the higher values of the index must have
greater predictive power.

Table XVIII. FDA Clinical Trials (phase II interventional studies) 1999-2017 (FDA
Database, 2017).
Sponsor

Clinical Trial Title

Disease

Prevalence

Participation

Duration

Allergan

A study of 2 dose of

Asthma

26,000,000

560 adults

74

MAP0010 in asthmatics

(Common

adults.

disease).

Afferent

A study to assess the

Idiopathic

Pharmaceuticals,

tolerability of a single

pulmonary

Inc.

dose of Gefapixant (AF-

fibrosis (IPF)

219/MK-7264)

(Rare disease).

in

months

20,000

6 adults

subjects with Idiopathic
Pulmonary

Fibrosis

(IPF).
Source: clinialtrial.gov results from 02/21/2018

20
months
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FDA database of clinical trial under phase 2 interventional trials from 1999-2017
was used. AODI scores were calculated for MAP0010 a new drug developed by Allergan
for the treatment of asthma in adults. 26 million adult Americans currently suffer from this
pathology. A total of 560 adults participated in this clinical trial phase two randomized test
that lasted 74 months (FDA database, 2018). This new drug MAP0010 developed for the
treatment of asthma scored zero (0) in the AODI index which is logical and expected.
Asthma is not a rare disease; it is a serious public health issue in the US that affects more
that 200,000 Americans and there are multiple treatment and therapies available in the US
market for it diagnose and treatment. However, the example of Gefapixant (AF-219/MK7264), an orphan drug developed by Afferent Pharmaceuticals, Inc. for the treatment of
idiopathic pulmonary fibrosis (IPF) a well-known rare condition (FDA database, 2018).
IPF is a serious and debilitating rare disease that produce scaring of the lungs tissue. In the
US only 20,000 adults suffer from this life-threating disease. Gefapixant (AF-219/MK7264) scored two (2) in the AODI index. AODI was tested over 20 times using similar
examples in 2018.

Data from orphan drugs versus non-orphans (within the same

therapeutic class) was tested and the results were very consistent (see Chapter IV validation
and standardization of Approved Orphan Drug Index). AODI proves valid and can be used
as a diagnostic tool in portfolio decision making of orphan drug regulatory approval.

Pharmaceutical companies have long used estimates of probability of regulatory
success for orphan drugs in general and by therapeutic class as inputs in their decisionmaking regarding the formulation of their portfolios of investigational drugs and whether
at various critical points during the development process to abandon or proceed. An easy-
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to-apply algorithm was created to assist those decisions for orphan drugs registration. The
AODI (Algorithm Orphan Drug Index) scoring metric was shown to be strongly associated
with probability of regulatory success. The algorithm depends on only three factors, with
its scale running from 0 to 2. The three factors were inversely related with probability of
regulatory success of orphan drugs and the underlying rationales for their effects are less
straightforward. The speed with which phase II testing was conducted may be an indicator
of operational excellence and it could be an indication that the treatment community
recognizes that the orphan drug has the potential to make a significant contribution to
patient care. Finally, an inverse relationship between prevalence and approval success rates
may indicate the lack of a recognized standard of care, more accurately defined patient
populations, a lower hurdle for regulatory approval, or some combination of these
conditions. An advantage of the AODI metric is that it will help pharmaceutical companies
to assign more appropriate probabilities of regulatory success to good drugs.
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Conceptual Frame Proposal based on
After evaluating results, the conceptual framework for orphan drug regulatory
Meta-Analysis
Results

Revised conceptual framework
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approval
looks as follow:

Clinical trials
Participation
p.= 0.0010
OR=13.606

Rare Disease
Prevalence
p.= 0.0020
OR= 0.170
+

+

=

PRS
Orphan drug

Clinical trials
Duration
p.=0.0015
OR=3.230

Figure 18. Revised conceptual framework for Probability of Regulatory Success of
Orphan Drugs (Florent, 2018).

In chapter II, it was mentioned that all factors extracted from the literature review
such as development cost, clinical trial duration, clinical trial participation and orphan drug
tax credit contributed equally to the probability of regulatory success of orphan drugs.
Today however, after conducting a systematic review of all the studies published and data
available in the public domain. It is possible to confidently suggest that clinical trial
participation, clinical trial duration and rare disease prevalence are the only factors that
play a key role in association to the probability of regulatory success of orphan drugs.
Figure 18. above shows study weight (odds ratio) to each factor that showed statistically
significant association (in isolation) with probability of regulatory success however these
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results do not mean that one factor weights more than the other when assessing the
probability of regulatory success of orphan drugs. Clinical trial participation reported a
high odds ratio as it intimately linked to rare disease prevalence. The low the rare disease
prevalence the lower the clinical trial participation. It is also noteworthy to mention that
reporting weights (odd ratio) is a very important requirement for the validity and reliability
of a meta-regression.

Revised algorithm for orphan drugs regulatory risk assessment

Based on results obtained from the quantitative Meta-analysis, the original
proposed algorithm was adjusted as follow:

Figure 19. Revised Algorithm for Probability of Regulatory Assessment of Orphan Drugs
(Florent, 2018)
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Absent of validation datasets, and cognizant of the need to address generalizability,
cross-validation was performed. While this technique does not eliminate the chance that
selection bias influenced the results, the convergence of many repetitions on the same
conclusions provides some assurance that the results are not overfit to the sample size used

Revised Algorithm for Orphan Drugs
Regulatory Approval Risk Assessment

in this study.
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PRS (MAP0010 ) =
1
x 1000 = 0,0003846*
560 (n) + 26,000,000 (N)+ 74 (t)

PRS (AF-219/MK-7264 ) =

1
x 1000 = 0.049
6 (n) + 20,000 (N)+ 20 (t)

Figure 21. Calculations of Probability of Regulatory Success for Orphan and Non-Orphan
Drugs (Florent, 2018)

In Figure 20. Using the same information of drugs found in FDA clinical trial
database, a comparison was conducted between a non-orphan drug developed for the
treatment of asthma versus an orphan drug developed for the treatment of idiopathic
pulmonary fibrosis (IPF) .The first result from the non-orphan drug is null as this formula
has been validated to be used only for orphan drug regulatory assessment meaning it is not
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specific for non-orphan drugs. Factors associated with regulatory approval of non-orphan
drugs are different in nature to orphan drugs as stated in the literature review. It is key to
evaluate and consider other factors such as competition and company size which are not
integrated in this formula hence it is not appropriate. The second result, however, is more
appropriate and mathematical acceptable as it shows in Figure 21. It is not only appropriate
to use the algorithm that has been validated for the assessment of regulatory approval of
orphan drugs, but the results derived from this mathematical formula is absolute and
correct. In the AODI index high scores are associated with high probability of regulatory
success whereas in this mathematical formula (algorithm), values closer to one (1) is an
good indicator of high probability of regulatory success of orphan drugs.

At the moment, it is not suggested that the scoring algorithm be used in a robotic
fashion to make go/no-go decisions for orphan drugs in development, but rather that it be
considered along with traditional success rate metrics and considerations specific to the
drug in question. Using an algorithm to assign probability of regulatory success is not
meant to preclude failure, nor is it meant to limit risk taking. Instead, assessing probability
of regulatory success using an algorithm-based method might help to push resources into
drugs for which support is logical and to limit ill-conceived risk taking of the sort that
consumes considerable research and development resources.
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Study Limitations

1) Personal bias: Empirical and practical knowledge of the regulatory process of drug
approval specifically of orphan drugs. This limitation was mitigated by following
Cochrane protocol for data gathering and a modified Delphi process with advisor
(Hasson, 2000) to make sure the inclusion and exclusion criteria were applied
appropriately without bias.

2) Generalization: In this case, because the lead researcher was conducting a quantitative
meta-analysis the assumption is that the results are representative of all literature. This
study limitation was mitigated by following Cochrane protocol.

3) Software availability: Specialized software CMAÒ and IBMÔSPSSÒ regression was
needed to conduct a quantitative meta-analysis. Lead researcher took advance statistical
classes and used special meta-analysis software to ensure the results reflected are
indeed correct.

4) Time and resources: this research was an intensive and thoughtful process that must be
engaged for years, therefore time and financial investment is necessary to make proper
connections and reasonable results outcomes. As lead researcher I mastered time–
management as well as developed a personal tool to organize and classify studies.
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5) Finally, having an excellent relationship with chair and committee. Makes all the
difference. Being able to communicate honestly and effectively with the chair is
essential including knowledge about the problem being sought to be analyzed. This
level of support was critical to complete this study.
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CHAPTER VI
CONCLUSION

Many factors were identified, compared and evaluated. Clinical trial duration,
clinical trial participation and rare disease prevalence showed significant results as
predicting factors in orphan drug approval as a result a revised algorithm specific for
assessment of orphan drug risks was created.

The AODI metric and the results obtained can be viewed as part of the effort to
improve drug portfolio decision-making. It would be helpful to obtain more complete data
on orphan drugs than the one currently from the public domain. This is particularly true for
clinical trial outcomes, especially safety characteristics. Additional information about
characteristics of the drugs themselves and how those characteristics relate to targets and
genetics could potentially also be very useful.

Pharmaceutical companies will now have a standardized tool that can be used to
predict regulatory success. This academic incentive will encourage pharmaceutical
companies to invest confidently in orphan drugs research and development. This model
can now be tested and validated using the FDA drug approval database since the factors
associated are link directly to the data available in the FDA approval database.
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Future Research
It has been established that the next step of this research is to use data available in
public domain about clinical trials for orphan drugs during phase III and use it to test the
proposed algorithm as it was not tested for sensitivity and specificity. In addition, it would
be a good idea to liaise with FDA office of Orphan Product Development to obtain specific
data and calibrate proposed algorithm. It is the intention of this study to offer the proposed
algorithm to senior leaders in the pharmaceutical industry who are looking to expand their
orphan drug portfolio and study the real-life applicability.

Finally, it is the ultimate goal of this study to learn as much as possible about the
tool and evaluate future pharmaceutical trends for example to create similar tool for ultrarare diseases (<50,000) and rare cancers (identified industry trend).

Dissertation Significance and Conclusion
This study provides an objective means by which any pharmaceutical company can
do a reasonable and reliable calculated risk analysis for orphan drug regulatory assessment
and consequently increase orphan drug designation (ODD) in the US. By doing so, the
industry will be increasing orphan drug access to patients.

Meta-analysis is an excellent tool to identify and evaluate factors associated with
orphan drug approval in order to ascertain a reasonable and relevant algorithm that could
be used in the industry.
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Meta-analysis is valuable as a research methodology when prospective studies are
not possible due to, for example, proprietary information not being allowed to be used for
research purposes.

Meta-analysis provided a standardized approach for examining the existing
literature on Orphan drug regulatory approval and its results refuted expert opinion and
misconceptions.
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